Cellular Biomedicine (CBMG) 10-K/A13 Apr 152014 FY Annual report (amended)Financial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Mar. 18, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	Cellular Biomedicine Group, Inc.
Entity Central Index Key	1378624
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$17,576,496
Entity Common Stock, Shares Outstanding		10,995,235
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014		Dec. 31, 2013
Assets
Cash and cash equivalents	$14,770,584		$7,175,215
Accounts receivable	141,029		10,581
Other receivable	135,957		78,521
Inventory	372,249		119,119
Prepaid expenses	565,299		56,911
Other current assets	110,347		134,661
Total current assets	16,095,465		7,575,008
Investments	6,886,033		5,105,891
Property, plant and equipment, net	1,280,410		1,014,805
Goodwill	7,678,789		3,299,566
Intangibles, net	11,156,676		601,456
Long-term prepaid expenses and other assets	587,729
Total assets (1)	43,685,102	[1]	17,596,726	[1]
Liabilities and Stockholders' Equity
Accounts payable	426,917		213,891
Accrued expenses	2,074,384		503,717
Taxe payable	814,288		1,164,747
Advances payable to related party	36,254		67,999
Other current liabilities	724,479		251,299
Total current liabilities	4,076,322		2,201,653
Other non-current liabilities	452,689
Total liabilities (1)	4,529,011	[1]	2,201,653	[1]
Commitments and Contingencies
Stockholders' equity:
Preferred stock, par value $.001, 50,000,000 shares authorized; none issued and outstanding as of December 31, 2014 and 2013, respectively
Common stock, par value $.001, 300,000,000 shares authorized; 10,990,335 and 7,382,797 issued and outstanding as of December 31, 2014 and 2013, respectively	10,990		7,383
Additional paid in capital	75,467,316		37,861,593
Accumulated deficit	-37,890,590		-22,415,979
Accumulated other comprehensive income (loss)	1,568,375		-57,924
Total stockholders' equity	39,156,091		15,395,073
Total liabilities and stockholders' equity	$43,685,102		$17,596,726

[1]	The Company's consolidated assets as of December 31, 2014 and 2013 included $5,508,459 and $1,031,350, respectively, of assets of variable interest entities, or VIEs, that can only be used to settle obligations of the VIEs. Each of the following amounts represent the balances as of December 31, 2014 and 2013, respectively. These assets include cash and cash equivalents of $3,496,678 and $9,100; accounts receivable of $141,029 and $0; other receivables of $127,280 and $50,383; inventory of $215,152 and $26,526; prepaid expenses of $193,613 and $33,015; other current assets of $109,777 and $84,661; property, plant and equipment, net, of $1,055,648 and $772,872; and intangibles of $42,779 and $54,793; long-term prepaid expenses and other assets of $126,503 and $0. The Company's consolidated liabilities as of December 31, 2014 and 2013 included $1,434,826 and $387,703, respectively, of liabilities of the VIEs whose creditors have no recourse to the Company. These liabilities include accounts payable of $10,572 and $24,868; other payables of $714,309 and $268,301; payroll accrual of $273,599 and $74,384; and tax payable of $0 and $20,150 and other non-current liabilities of $436,346 and $0. See further description in Note 6, Variable Interest Entity.

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Stockholders' equity:
Preferred stock par value	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, Authorized	300,000,000	300,000,000
Common stock, Issued	10,990,335	7,382,797
Common stock, outstanding	10,990,335	7,382,797

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Condensed Consolidated Statements Of Operations And Comprehensive Income Loss
Net sales and revenue	$564,377	$204,914
Operating expenses:
Cost of sales	213,243	296,212
General and administrative	8,413,251	9,314,143
Selling and marketing	280,595	57,670
Research and development	2,671,932	1,890,506
Impairment of investments	1,427,840
Total operating expenses	13,006,861	11,558,531
Operating loss	-12,442,484	-11,353,617
Other income (expense):
Interest income	15,043	1,294
Other income (expense)	71,982	-6,196
Total other income (expense)	87,025	-4,902
Loss from continuing operations before taxes	-12,355,459	-11,358,519
Income tax provision
Loss from continuing operations	-12,355,459	-11,358,519
Loss on discontinued operations, net of tax	-3,119,152	-2,438,514
Net loss	-15,474,611	-13,797,033
Other comprehensive income (loss):
Cumulative translation adjustment	15,254	78,650
Unrecognized gain (loss) on investments	1,611,045	-198,200
Total other comprehensive income (loss):	1,626,299	-119,550
Comprehensive loss	($13,848,312)	($13,916,583)
Earnings (loss) per share for continuing operations:
Basic	($1.43)	($1.96)
Diluted	($1.43)	($1.96)
Earnings (loss) per share discontinued operations:
Basic	($0.36)	($0.42)
Diluted	($0.36)	($0.42)
Earnings (loss) per share net loss:
Basic	($1.79)	($2.38)
Diluted	($1.79)	($2.38)
Weighted average common shares outstanding:
Basic	8,627,094	5,792,888
Diluted	8,627,094	5,792,888

Statement_CONSOLIDATED_STATEME

Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $)	Common Stock	Preferred Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income(Loss)	Total
Beginning Balance, amount at Dec. 31, 2012	$3,711		$14,710,002	($8,618,946)	$61,626	$6,156,393
Beginning Balance, shares at Dec. 31, 2012	3,710,560
Common stock issued for services, shares	231,384					231,384
Common stock issued for services, amount	231		1,156,868			1,157,099
Common stock issued with PPM, shares	1,434,778
Common stock issued with PPM, amount	1,435		8,990,956			8,992,391
Stock based compensation, shares	93,416					65,000
Stock based compensation, amount	93		736,559			736,652
Reverse merger with EastBridge, shares	1,570,299
Reverse merger with EastBridge, amount	1,571		9,780,223			9,781,794
Contingent stock issuance, shares	342,360					342,360
Contingent stock issuance, amount	342		1,694,340			1,694,682
Accrual of restricted stock grants			255,993			255,993
Accrual of stock options			536,652			536,652
Common stock issued for acquisition
Unrecognized gain/loss on investments					-198,200	-198,200
Foreign currency translation					78,650	78,650
Net Income (loss)				-13,797,033		-13,797,033
Ending Balance, amount at Dec. 31, 2013	7,383		37,861,593	-22,415,979	-57,924	15,395,073
Ending Balance, shares at Dec. 31, 2013	7,382,797
Common stock issued for services, shares	43,760
Common stock issued for services, amount	44		578,937			578,981
Common stock issued with PPM, shares	1,686,566
Common stock issued with PPM, amount	1,686		11,120,270			11,121,956
Stock based compensation, shares	13,413					13,413
Stock based compensation, amount	13		207,188			207,201
Reverse merger with EastBridge, shares						1,570,299
Accrual of restricted stock grants, shares	13,862
Accrual of restricted stock grants, amount	14		106,378			106,392
Accrual of stock options			1,636,311			1,636,311
Exercise of stock options, shares	3,650					3,650
Exercise of stock options	4		19,383			19,387
Exercise of warrant issued in PPM, shares	1,017,765
Exercise of warrant issued in PPM	1,018		7,998,978			7,999,996
Common stock issued for acquisition, shares	828,522
Common stock issued for acquisition	828		15,938,278			15,939,106
Unrecognized gain/loss on investments					1,611,045	1,611,045
Foreign currency translation					15,254	15,254
Net Income (loss)				-15,474,611		-15,474,611
Ending Balance, amount at Dec. 31, 2014	$10,990		$75,467,316	($37,890,590)	$1,568,375	$39,156,091
Ending Balance, shares at Dec. 31, 2014	10,990,335

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($15,474,611)	($13,797,033)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,190,505	841,235
Loss on disposal of assets	257,672
Stock based compensation expense	1,949,908	4,381,077
Other than temporary impairment	1,427,840
Impairment of goodwill	3,299,566	4,258,967
Third party services received in exchange for disposition of investment stock		83,334
Loss recognized in excess of cash received on disposition of investment stock	5,913	138,909
Value of stock received for services	-1,610,000	-3,500,000
Deferred tax		-76,544
Changes in operating assets and liabilities:
Accounts receivable	20,645	10,102
Other receivable	-25,638	50,160
Inventory	-78,310	-81,878
Prepaid expenses	-494,057	-38,793
Other current assets	24,314	-84,661
Investments	7,150
Long-term prepaid expenses and other assets	-504,678	134,229
Accounts payable	165,517	40,862
Accrued expenses	409,109	-739,839
Other current liabilities	-694,131	186,464
Taxes payable	-176,583	-10,121
Deferred revenue		-251,834
Net cash used in operating activities	-10,299,869	-8,455,364
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of business, net of cash acquired	-1,485,548
Purchases of intangibles	-8,989	-5,828
Purchases of assets	-311,625	-147,211
Net cash provided by (used in) investing activities	-1,806,162	-153,039
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of common stock	19,700,933	11,561,386
Proceeds from exercise of stock options	19,383
Repayment of advances from affiliate	-31,745	-1,250
Advances from affiliate		36,614
Net cash provided by financing activities	19,688,571	11,596,750
EFFECT OF EXCHANGE RATE CHANGES ON CASH	12,829	41,972
INCREASE IN CASH AND CASH EQUIVALENTS	7,595,369	3,030,319
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	7,175,215	4,144,896
CASH AND CASH EQUIVALENTS, END OF PERIOD	14,770,584	7,175,215
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for income taxes	460,924
Non cash financing and investing activities:
Issuance of company stock for accrued liabilities and advances		149,475
Issuance of company stock for acquisition of patent	1,442,850
Issuance of company stock for acquisition of business	$14,496,256

1_DESCRIPTION_OF_BUSINESS

1. DESCRIPTION OF BUSINESS	12 Months Ended
1. DESCRIPTION OF BUSINESS	Dec. 31, 2014
Notes to Financial Statements
1. DESCRIPTION OF BUSINESS	As used in this report, "we", "us", "our", "CBMG", "Company" or "our company" refers to Cellular Biomedicine Group, Inc. and, unless the context otherwise requires, all of its subsidiaries.

	Overview

	Cellular Biomedicine Group, Inc. is a biomedicine company, principally engaged in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. Our technology includes two major cell platforms: (i) Immune Cell therapy for treatment of a broad range of cancers, (ii) haMPC (human adipose-derived mesenchymal progenitor cells) for treatment of joint and autoimmune diseases.

	We are focused on developing and marketing safe and effective cell-based therapies based on our cellular platforms, to treat serious chronic and degenerative diseases including cancers, orthopedic diseases including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases. We have developed proprietary practical knowledge in the use of cell-based therapeutics that we believe could be used to help a great number of people suffering from cancer and serious chronic diseases. We have one major therapy undergoing clinical studies in China: stem cell based therapies to treat knee osteoarthritis (“KOA”). We have initiated preclinical studies in Asthma, and Chronic Obstructive Pulmonary Disease ("COPD") and clinical research studies in cartilage defect stem cell therapy.

	Our primary target market is Greater China. Our first two therapy candidates are currently used to treat patients in research studies conducted in China. We are also engaged in a number of pre-clinical studies for other product or therapy candidates, which we believe have the potential to become safe and effective treatment options for a variety of degenerative and debilitating conditions. We believe that the results of our research studies will support expanded preclinical and clinical trials with a larger population of patients, which we expect to carry out through authorized treatment centers throughout Greater China. With the recent acquisition of Agreen Biotech Co. Ltd. ("AG") we added budding technical services revenue comprised of T Cells Receptor ("TCR") clonality analysis technology and T Central Memory Cell ("Tcm") and Dendritic Cell ("DC") preparation methodologies.

	Corporate History

	Cellular Biomedicine Group, Inc., (formerly known as EastBridge Investment Group Corporation) was originally incorporated in the State of Arizona on June 25, 2001 under the name ATC Technology Corporation. ATC Technology Corporation changed its corporate name to EastBridge Investment Group Corporation in September 2005 and changed its business focus to providing investment related services in Asia, with a strong focus on high GDP growth countries, such as China. The Company provides consulting services necessary for small to medium-sized companies to obtain capital to grow their businesses. The Company assists its clients in locating investment banking, financial advisory and other financial services necessary to become public companies in the United States or find joint venture partners or raise capital to expand their businesses.

	On November 13, 2012, EastBridge Investment Group Corporation, an Arizona corporation (“EastBridge”), CBMG Acquisition Limited, a British Virgin Islands company and the Company’s wholly-owned subsidiary (“Merger Sub”) and Cellular Biomedicine Group Ltd. (“CBMG BVI”), a British Virgin Islands company, entered into a Merger Agreement, pursuant to which CBMG BVI was the surviving entity in a merger with Merger Sub whereby CBMG BVI became a wholly-owned subsidiary of the Company (the “Merger”). The Merger was consummated on February 6, 2013 (the “Closing Date”). Upon consummation of the Merger, CBMG BVI shareholders were issued 3,638,941 shares of common stock, par value $0.001 per share, of the Company (the “Company Common Stock”) constituting approximately 70% of the outstanding stock of the Company on a fully-diluted basis and the then current Company shareholders retained approximately 30% of the Company on a fully-diluted basis. Specifically, each of CBMG BVI’s ordinary shares (“CBMG BVI Ordinary Shares”) were converted into the right to receive 0.020019 shares of Company Common Stock.

	Also in connection with the Merger, the Company created a new Delaware subsidiary named EastBridge Investment Corp. (“EastBridge Sub”). Pursuant to a Contribution Agreement by and between the Company and EastBridge Sub dated February 5, 2013, the Company contributed all of its then current assets and liabilities to EastBridge Sub which continued the business and operations of the Company at the subsidiary level. A copy of the Contribution Agreement is attached as Exhibit 10.1 to the Current Report on Form 8-K filed by the Company on February 12, 2013.

	As a result of the Merger, CBMG BVI and EastBridge Sub became the two direct subsidiaries of the Company.

	In connection with the Merger, effective March 5, 2013, the Company (formerly named “EastBridge Investment Group Corporation”) changed its name to “Cellular Biomedicine Group, Inc.” In addition in March 2013, the Company changed its corporate headquarters to 530 University Avenue in Palo Alto, California.

	From February 6, 2013 to June 23, 2014, we operated the Company in two separate reportable segments: (i) Biomedicine Cell Therapy (“Biomedicine”); and (ii) Financial Consulting (“Consulting”). The Consulting segment is conducted through EastBridge Sub. On June 23, 2014, the Company announced the discontinuation of the Consulting segment as it no longer fits into management’s long-term strategy and vision. The Company will focus resources on becoming a pure-play biotechnology company bringing therapies to improve the health of patients in China.

	On September 26, 2014, the Company completed its acquisition of AG and the U.S. patent held by AG’s founder.

	AG is a biotech company with operations in China, engaged in the development of treatments for cancerous diseases utilizing proprietary cell technologies, which include without limitation, preparation of subset T Cell and clonality assay platform technology for treatment of a broad range of cancers by AG’s served hospital, Jilin Hospital.

	AG is focused on developing and marketing its technical service and test kits to hospitals that treat cancer patients who are undergoing immune cell therapy classified as 3rd Medical Technology by regulatory agencies in China. We have developed proprietary practical knowledge in the use of cell-based therapeutics that we believe could be used to help a great number of people suffering from cancer. Specifically, we provide technical services comprised of T Cell Receptors ("TCR") clonality analysis technology and T Central Memory Cell ("Tcm") and Dendritic Cell ("DC") preparation methodologies. The TCR clonality analysis technology is based on the use of the multiple sets of unique primers to amplify 22 regions of the TCR and thereby detect clonal expansions related to antigen stimulation of the immune system, which enables the assessment of tumor specific immunity with high accuracy and efficiency. Tcm cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity; and they are the key element of immunocellular fortification against tumors, infections and immune disorders. The Tcm cells are drawn from the cancer patient’s own blood and the therapy using these cells is classified in China as Medical Technology, which enables such therapy to be covered by medical insurance in more than ten provinces in China.

	AG’s primary market is China. Jilin Hospital, AG’s primary hospital partner, currently uses AG’s technical services and test kits to treat patients who are undergoing cancer immune cell therapy in China. Based on AG’s results to date, AG believes that its TCR and Tcm services are safe and effective treatment options for cancer patients.

2_BASIS_OF_PRESENTATION

2. BASIS OF PRESENTATION	12 Months Ended
2. BASIS OF PRESENTATION	Dec. 31, 2014
Notes to Financial Statements
2. BASIS OF PRESENTATION	As of February 6, 2013, in connection with the Merger, Cellular Biomedicine Group, Ltd. was determined to be the accounting acquirer thus resulting in a reverse merger for accounting purposes. Therefore, the accompanying financial statements are on a consolidated basis subsequent to February 6, 2013, but only reflect the operations of CBMG BVI. prior to the date of acquisition.

	The Company acquired AG on September 26, 2014 and the accompanying financial statements only reflect operations subsequent to such date.

3_SUMMARY_OF_SIGNIFICANT_ACCOU

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:

	Principles of Consolidation

	The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, or GAAP, and reflect the accounts and operations of the Company and its majority or wholly-owned subsidiaries, beginning with the date of their respective acquisition. In accordance with the provisions of Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) Section 810, or ASC 810, Consolidation, the Company consolidates any variable interest entity, or VIE, of which it is the primary beneficiary. The typical condition for a controlling financial interest ownership is holding a majority of the voting interests of an entity; however, a controlling financial interest may also exist in entities, such as variable interest entities, through arrangements that do not involve controlling voting interests. ASC 810 requires a variable interest holder to consolidate a VIE if that party has the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance, and the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company does not consolidate a VIE in which it has a majority ownership interest when the Company is not considered the primary beneficiary. The Company has determined that it is the primary beneficiary in a VIE—refer to Note 6, Variable Interest Entity. The Company evaluates its relationships with the VIE on an ongoing basis to ensure that it continues to be the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.

	Use of Estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements.

	These estimates and assumptions also affect the reported amounts of revenues, costs and expenses during the reporting period. Management evaluates these estimates and assumptions on a regular basis. Actual results could materially differ from those estimates.

	Revenue Recognition

	The Company utilizes the guidance set forth in the Securities and Exchange Commission's Staff Accounting Bulletin (SAB) No. 104, regarding the recognition, presentation and disclosure of revenue in its financial statements.

	For its Consulting segment, the Company engaged in listing contracts with its clients which provide for the payment of fees, either in cash or equity, upon the achievement of certain milestones by the client, including the successful completion of a financial statement audit, the successful listing on a national stock exchange or over-the-counter market and the maintenance of ongoing 1934 Act reporting requirements with the Securities and Exchange Commission. In some instances, payment may be made in advance of performance; however, such payment was often refundable in the event that milestones were not reached. The Company recognized revenue as milestones are reached in accordance with FASB’s Accounting Standards Codification (ASC) No. 605-28-25. Such guidance stipulates that revenue be recognized for individual elements in a multiple deliverable arrangement using the relative selling price method. The Company relied on internal estimates of the relative selling price of each element as objective third-party evidence is unattainable. This segment was discontinued in 2014 and will not have further revenue.

	For its Biomedicine segment, the Company recognizes revenue when pervasive evidence of an arrangement exists, the price is fixed and determinable, collection is reasonably assured and delivery of products or services has been rendered. The Biomedicine segment has started to generate revenues with the acquisition of AG and expects to expand revenue generating activities significantly over the next two to five years as additional therapies are developed.

	Cash and Cash Equivalents

	The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At December 31, 2014 and 2013, respectively, cash and cash equivalents include cash on hand and cash in the bank. At times, cash deposits may exceed government-insured limits.

	Accounts Receivable

	Accounts receivable represent amounts earned but not collected in connection with the Company’s sales as of December 31, 2014 and 2013. Accounts receivable are carried at their estimated collectible amounts.

	The Company follows the allowance method of recognizing uncollectible accounts receivable. The Company recognizes bad debt expense based on specifically identified customers and invoices that are anticipated to be uncollectable. At December 31, 2014 and December 31, 2013, an allowance was determined to not be needed as the Company has recently started generating revenues from its cell therapy treatments in the Biomedicine segment in 2014. Correspondingly the Company has not recorded any bad debt expense for the periods ended December 31, 2014 and 2013, respectively.

	Inventory

	Inventories consist of finished goods, raw materials, work-in-process, and low value consumable materials. Inventories are initially recognized at cost and subsequently at the lower of cost and net realizable value under first-in first-out method. Finished goods are comprised of direct materials, direct labor, depreciation and manufacturing overhead. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose. The Company regularly inspects the shelf life of prepared finished goods and, if necessary, writes down their carrying value based on their salability and expiration dates into cost of goods sold.

	Property, Plant and Equipment

	Property, plant and equipment are recorded at cost. Depreciation is provided for on the straight-line method over the estimated useful lives of the assets ranging from three to ten years and begins when the related assets are placed in service. Maintenance and repairs that neither materially add to the value of the property nor appreciably prolong its life are charged to expense as incurred. Betterments or renewals are capitalized when incurred. Plant, property and equipment are reviewed each year to determine whether any events or circumstances indicate that the carrying amount of the assets may not be recoverable. We assess the recoverability of the asset by comparing the projected undiscounted net cash flows associated with the related assets over the estimated remaining life against the respective carrying value.

	For the years ended December 31, 2014 and 2013, depreciation expense was $586,679 and $495,029, respectively.

	Goodwill and Other Intangibles

	Goodwill represents the excess of the cost of assets acquired over the fair value of the net assets at the date of acquisition. Intangible assets represent the fair value of separately recognizable intangible assets acquired in connection with the Company’s business combinations. The Company evaluates its goodwill and other intangibles for impairment on an annual basis or whenever events or circumstances indicate that an impairment may have occurred. As part of the determination to discontinue the Consulting segment, in the second quarter of 2014, the Company expensed approximately $3,300,000 which represented the remaining goodwill from the 2013 merger. In December, 2013 the Company determined that the goodwill was impaired and therefore recorded impairment expense of $4,258,967.

	Income Taxes

	Income taxes are accounted for using the asset and liability method. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance would be provided for those deferred tax assets if it is more likely than not that the related benefit will not be realized.

	A full valuation allowance has been established against all net deferred tax assets as of December 31, 2014 and 2013 based on estimates of recoverability. While the Company has optimistic plans for its business strategy, we determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to the Company’s ability to generate sufficient profits from its business model.

	Share-Based Compensation

	The Company periodically uses stock-based awards, consisting of shares of common stock and stock options, to compensate certain officers and consultants. Shares are expensed on a straight line basis over the requisite service period based on the grant date fair value, net of estimated forfeitures, if any. We currently use the Black-Scholes option-pricing model to estimate the fair value of our stock-based payment awards. This model requires the input of highly subjective assumptions, including the fair value of the underlying common stock, the expected volatility of the price of our common stock, risk-free interest rates, the expected term of the option and the expected dividend yield of our common stock. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. These assumptions are estimated as follows:

	●	Fair Value of Our Common Stock — Our common stock is valued by reference to the publicly-traded price of our common stock.

	●	Expected Volatility — Prior to the Eastbridge merger, we did not have a history of market prices for our common stock and since the merger, we do not have what we consider a sufficiently active and readily traded market for our common stock to use historical market prices for our common stock to estimate volatility. Accordingly, we estimate the expected stock price volatility for our common stock by taking the median historical stock price volatility for industry peers based on daily price observations over a period equivalent to the expected term of the stock option grants. Industry peers consist of other public companies in the stem cell industry similar in size, stage of life cycle and financial leverage. We intend to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of our own common stock share price becomes available.

	●	Risk-Free Interest Rate — The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of our awards. The risk-free interest rate assumption is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options for each option group.

	●	Expected Term — The expected term represents the period that our stock-based awards are expected to be outstanding. The expected terms of the awards are based on a simplified method which defines the life as the average of the contractual term of the options and the weighted-average vesting period for all open tranches.

	●	Expected Dividend Yield — We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. Consequently, we used an expected dividend yield of zero.

In addition to the assumptions used in the Black-Scholes option-pricing model, the amount of stock option expense we recognize in our consolidated statements of operations includes an estimate of stock option forfeitures. We estimate our forfeiture rate based on an analysis of our actual forfeitures and will continue to evaluate the appropriateness of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover and other factors. Changes in the estimated forfeiture rate can have a significant impact on our stock-based compensation expense as the cumulative effect of adjusting the rate is recognized in the period the forfeiture estimate is changed. If a revised forfeiture rate is higher than the previously estimated forfeiture rate, an adjustment is made that will result in a decrease to the stock-based compensation expense recognized in the consolidated financial statements. If a revised forfeiture rate is lower than the previously estimated forfeiture rate, an adjustment is made that will result in an increase to the stock-based compensation expense recognized in our consolidated financial statements.

Fair Value of Financial Instruments

Under the FASB’s authoritative guidance on fair value measurements, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated or generally unobservable inputs. The Company uses valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based on observability of the inputs used in the valuation techniques, the Company is required to provide the following information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:

Level 1: Valuations for assets and liabilities traded in active exchange markets. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

Level 2: Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third party pricing services for identical or similar assets or liabilities.

Level 3: Valuations for assets and liabilities that are derived from other valuation methodologies, including option pricing models, discounted cash flow models and similar techniques, and not based on market exchange, dealer or broker traded transactions. Level 3 valuations incorporate certain unobservable assumptions and projections in determining the fair value assigned to such assets.

All transfers between fair value hierarchy levels are recognized by the Company at the end of each reporting period. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an investment’s level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement in its entirety requires judgment, and considers factors specific to the investment. The inputs or methodology used for valuing financial instruments are not necessarily an indication of the risks associated with investment in those instruments.

The carrying amounts of other financial instruments, including cash, accounts payable and accrued liabilities, income tax payable and related party payable approximate fair value due to their short maturities.

Investments

The fair value of “investments” is dependent on the type of investment, whether it is marketable or non-marketable.

Marketable securities held by the Company are held for an indefinite period of time and thus are classified as available-for-sale securities. The fair value is based on quoted market prices for the investment as of the balance sheet date. Realized investment gains and losses are included in the statement of operations, as are provisions for other than temporary declines in the market value of available for-sale securities. Unrealized gains and unrealized losses deemed to be temporary are excluded from earnings (losses), net of applicable taxes, as a component of other comprehensive income (loss). Factors considered in judging whether an impairment is other than temporary include the financial condition, business prospects and creditworthiness of the issuer, the length of time that fair value has been less than cost, the relative amount of decline, and the Company’s ability and intent to hold the investment until the fair value recovers.

The carrying amounts of other financial instruments, including cash, accounts payable and accrued liabilities, income tax payable and related party payable approximate fair value due to their short maturities.

Basic and Diluted Net Loss Per Share

Diluted income (loss) per share reflects potential dilution from the exercise or conversion of securities into common stock. The dilutive effect of the Company's share-based awards is computed using the treasury stock method, which assumes that all share-based awards are exercised and the hypothetical proceeds from exercise are used to purchase common stock at the average market price during the period. Share-based awards whose effects are anti-dilutive are excluded from computing diluted income (loss) per share. Due to the net loss, all common stock equivalents are anti-dilutive for the years ended December 31, 2014 and 2013.

Foreign Currency Translation

The Company's financial statements are presented in U.S. dollars ($), which is the Company’s reporting currency, while some of the Company’s subsidiaries’ functional currency is Chinese Renminbi (RMB). Transactions in foreign currencies are initially recorded at the functional currency rate ruling at the date of transaction. Any differences between the initially recorded amount and the settlement amount are recorded as a gain or loss on foreign currency transaction in the consolidated statements of operations. Monetary assets and liabilities denominated in foreign currency are translated at the functional currency rate of exchange ruling at the balance sheet date. Any differences are recorded as an unrealized gain or loss on foreign currency translation in the statements of operations and comprehensive loss. In accordance with ASC 830, Foreign Currency Matters, the Company translates the assets and liabilities into USD from RMB using the rate of exchange prevailing at the applicable balance sheet date and the statements of income and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation are recorded in shareholders' equity as part of accumulated other comprehensive income. The PRC government imposes significant exchange restrictions on fund transfers out of the PRC that are not related to business operations. These restrictions have not had a material impact on the Company because it has not engaged in any significant transactions that are subject to the restrictions.

Comprehensive Loss

We apply ASC No. 220, Comprehensive Income (ASC 220). ASC 220 establishes standards for the reporting and display of comprehensive income or loss, requiring its components to be reported in a financial statement that is displayed with the same prominence as other financial statements. Our comprehensive loss was $13,848,312 and $13,916,583 for the years ended December 31, 2014 and 2013, respectively.

Reclassification

Certain prior period amounts have been reclassified to conform to current year presentations. There was no change to previously reported stockholders’ deficit or net loss.

Segment Information

FASB ASC No. 280, “Segment Reporting” establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group in deciding how to allocate resources and in assessing performance. Following the discontinuance of our consulting business, we operate in a single reportable segment.

Recent Accounting Pronouncements

Recent accounting pronouncements that the Company has adopted or may be required to adopt in the future are summarized below.

In February 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis” (“ASU 2015-02”). The amendments in this update affect reporting entities that are required to evaluate whether they should consolidate certain legal entities. All legal entities are subject to reevaluation under the revised consolidation model. ASU 2015-02 is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-02 on our consolidated financial statements.

In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). The amendments in this update require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. We are currently in the process of evaluating the impact of the adoption of ASU 2014-15 on our consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in “Revenue Recognition (Topic 605)”, and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early adoption is not permitted. We are currently in the process of evaluating the impact of the adoption of ASU 2014-09 on our consolidated financial statements.

In April 2014, the FASB issued ASU 2014-08, “Presentation of Financial Statements (Topic205)” and “Property Plant and Equipment (Topic 360)”. The amendments in this ASU modify the requirements for the reporting of discontinued operations. In order to qualify as a discontinued operation, the disposal of a component of an entity, a group of components, or a business of an entity must represent a strategic shift that has (or will have) a major effect on an entity's operations and financial results. The ASU further indicates that the timing for recording a discontinued operation is when one of the following occurs: the component, group of components, or business meets the criteria to be classified as held-for-sale; the component, group of components, or business is disposed of by sale; or the component, group of components, or business is disposed of other than by sale (for example abandonment or spinoff). In addition, the ASU also requires additional disclosure items about an entity's discontinued operations. The amendments are effective for us beginning on January 1, 2015. The amendments are to be applied prospectively solely to newly identified disposals that qualify as discontinued operations after the effective date. Items previously reported as discontinued operations will maintain their classification based on the prior guidance. Early adoption is permitted, but only for disposals that have not been previously reported as discontinued operations in previously issued financial statements. We are currently in the process of evaluating the impact of the adoption of ASU 2014-08 on our consolidated financial statements.

4_BUSINESS_COMBINATION

4. BUSINESS COMBINATION	12 Months Ended
4. BUSINESS COMBINATION	Dec. 31, 2014
Notes to Financial Statements
4. BUSINESS COMBINATION	On September 26, 2014, the Company acquired all of the outstanding equity of Agreen Biotech Co. Ltd. ("AG") in exchange for cash of $3,240,000 and the issuance of 753,522 shares of its common stock. Based on the closing price of the common stock on September 26, 2014, the aggregate purchase price was $17,747,415. Of the cash consideration, $1,620,000 was unpaid as of December 31, 2014 and is reflected in accrued expenses in the accompanying consolidated balance sheet. As a result of the acquisition, AG became a wholly-owned subsidiary of CBMG Shanghai.

	The acquisition was accounted for as a business purchase pursuant to ASC Topic 805, Business Combinations. Under this ASC, acquisition and integration costs are not included as components of consideration transferred, but are accounted for as expenses in the period in which the costs are incurred. The Company incurred acquisition expense of approximately $480,000 directly related to this specific business combination. This expense is included in the 2014 general and administrative expenses presented on the statement of operations.

	AG is a cancer-therapy-focused company whose intellectual property (including the intellectual property of AG’s founder, which the Company also acquired) is comprised of T Cells Receptor ("TCR") clonality analysis technology and T Central Memory Cell ("Tcm") and Dendritic Cell ("DC") preparation methodologies.

	The following table provides the preliminary allocation of purchase price based on the estimated fair values of the assets acquired (including intangible assets) and liabilities assumed in connection with the acquisition:

	Cash	$	145,611
	Accounts receivable		151,093
	Other receivable		31,798
	Inventory		174,820
	Prepaid expenses		14,331
	Property, plant and equipment, net		561,113
	Intangible assets		9,942,000
	Goodwill		7,678,786
	Long-term prepaid expenses		83,054
	Total assets acquired		18,782,606

	Accounts payables		(47,509	)
	Accrued expenses		(42,013	)
	Other current liabilities		(523,077	)
	Other non current liabilities		(422,592	)
	Total liabilities assumed		(1,035,191	)

	Purchase price	$	17,747,415

	The intangible assets acquired consist of developed technology in connection with AG’s core business, which are being amortized over an estimated life of ten years. Goodwill was the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill is not amortized and is not deductible for tax purposes.

	In connection with the AG acquisition, the Company acquired existing patents and intellectual property that were owned by AG’s primary shareholder in exchange for 75,000 shares with a fair value of approximately $1,442,850. These assets are also reflected as intangible assets in the accompanying consolidated balance sheet at September 30, 2014 and are being amortized over an estimated life of 10 years.

	The following unaudited pro forma consolidated results of operations has been prepared as if the acquisition of AG and related patents and intellectual property described above had occurred on January 1, 2013 and includes adjustments for the amortization of intangibles and the earnings-per-share impacts of the issuance of shares as part of the acquisition of AG and related patents and intellectual property:

		Year Ended December 31, 2014									Year Ended December 31, 2013
		CBMG			Agreen			Pro forma			CBMG			Agreen			Pro forma
		As stated			Pro forma Adjustment			Consolidated			As stated			Pro forma Adjustment			Consolidated
	Net sales and revenue	$	564,377		$	1,198,414		$	1,762,791		$	204,914		$	1,075,692		$	1,280,606
	Net loss		(15,474,611	)		(48,109	)		(15,522,720	)		(13,797,033	)		(338,804	)		(14,135,837	)

	Weighted average common shares outstanding:
	Basic		8,627,094			555,335			9,182,429			5,792,888			753,522			6,546,410
	Diluted		8,627,094			555,335			9,182,429			5,792,888			753,522			6,546,410
	Earnings (loss) per share net loss:
	Basic	$	(1.79	)	$	(0.09	)	$	(1.69	)	$	(2.38	)	$	(0.45	)	$	(2.16	)
	Diluted	$	(1.79	)	$	(0.09	)	$	(1.69	)	$	(2.38	)	$	(0.45	)	$	(2.16	)

	All expenditures incurred in connection with this acquisition were expensed and are included in general and administrative expenses. Transaction costs incurred in connection with the acquisition were $611,511 during the year ended December 31, 2014. The Company recorded revenue of $378,329 and net loss of $125,025 from Agreen for the year ended December 31, 2014.

5_DISCONTINUED_OPERATIONS

5. DISCONTINUED OPERATIONS	12 Months Ended
5. DISCONTINUED OPERATIONS	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
5. DISCONTINUED OPERATIONS	On June 23, 2014, at a Board of Directors meeting, the Company approved the discontinuation of all activities of the Consulting segment. Accordingly, based on management’s intent at June 30, 2014, the Company discontinued the Consulting segment.

	As a result the Company’s activities for the Consulting segment at December 31, 2014 are now limited to winding down our consulting business activities, realizing the value of the Consulting segment’s remaining assets and making tax and regulatory filings related to the Consulting segment. Management’s goal is to liquidate all of the Consulting segment’s remaining assets as soon as practical while seeking to maximize stockholder value. All of the operations of the Consulting segment and all significant obligations to pay or make provisions to satisfy all of its expenses and liabilities will be concluded as soon as practicable. The Company intends to retain a sufficient amount of assets to ensure it is able to pay or satisfy all of the Consulting segment’s remaining expenses and liabilities. All costs associated with the discontinuation have been recorded as of December 31, 2014

	In conjunction with the discontinuance of operations, the Company recognized that all assets carrying amounts are recorded at their fair values less estimated cost to sell. The assets and liabilities of the discontinued operations are presented below under the captions ‘‘Assets of discontinued segment’’ and ‘‘Liabilities of discontinued segment,’’ respectively, in the accompanying Balance Sheets at December 31, 2014 and 2013, respectively, and consist of the following:

		December			December 31,
		2014			2013
	Assets of discontinued segment:

	Cash and cash equivalents	$	-		$	409,882
	Accounts receivable		-			10,581
	Other receivable		-			50,000
	Total current assets		-			470,463

	Goodwill		-			3,299,566
	Total assets	$	-		$	3,770,029

	Liabilities of discontinued segment:

	Accounts payable	$	-		$	110,373
	Accrued expenses		-			125,130
	Advances payable to related party		-			30,590
	Total liabilities	$	-		$	266,093


	Amounts presented for the years ended December 31, 2014 and 2013, have been reclassified to conform to the current presentation. The following table provides the amounts reclassified for the years ended December 31, 2014 and 2013:

		For the Year Ended
		December 31,
		2014			2013
	Amounts reclassified:
	Consulting revenue	$	1,612,746		$	3,864,586
	Consulting operating expenses		(1,352,189	)		(1,308,488	)
	Selling and marketing		(27,673	)		(70,069	)
	Impairment expense		(3,299,566	)		(4,258,967	)
	Other income (expense)		(1,725	)		(321,130	)
	Income tax provision		(50,745	)		(344,446	)
	Total amount reclassified as discontinued operations	$	(3,119,152	)	$	(2,438,514	)

6_VARIABLE_INTEREST_ENTITY

6. VARIABLE INTEREST ENTITY	12 Months Ended
6. VARIABLE INTEREST ENTITY	Dec. 31, 2014
Notes to Financial Statements
6. VARIABLE INTEREST ENTITY	VIEs are those entities in which a company, through contractual arrangements, bears the risk of, and enjoys the rewards normally associated with ownership of the entity, and therefore the company is the primary beneficiary of the entity. Cellular Biomedicine Group Ltd (Shanghai) (“CBMG Shanghai”) is a variable interest entity (VIE), through which the Company conducts stem cell research and clinical trials in China. The shareholders of record for CBMG Shanghai are Cao Wei and Chen Mingzhe, who together own 100% of the equity interests in CBMG Shanghai. The initial capitalization and operating expenses of CBMG Shanghai are funded by our wholly foreign-owned enterprise (“WFOE”), Cellular Biomedicine Group Ltd. (Wuxi) (“CBMG Wuxi”). The registered capital of CBMG Shanghai is ten million RMB and was incorporated on October 19, 2011.

	In February 2012, CBMG Wuxi provided financing to CBMG Shanghai in the amount of $1,587,075 for working capital purposes. In conjunction with the provided financing, exclusive option agreements were executed granting CBMG Wuxi the irrevocable and exclusive right to convert the unpaid portion of the provided financing into equity interest of CBMG Shanghai at CBMG Wuxi’s sole and absolute discretion. CBMG Wuxi and CBMG Shanghai additionally executed a business cooperation agreement whereby CBMG Wuxi is to provide CBMG Shanghai with technical and business support, consulting services, and other commercial services. The shareholders of CBMG Shanghai pledged their equity interest in CBMG Shanghai as collateral in the event CBMG Shanghai does not perform its obligations under the business cooperation agreement.

	The Company has determined it is the primary beneficiary of CBMG Shanghai by reference to the power and benefits criterion under ASC 810, Consolidation. This determination was reached after considering the financing provided by CBMG Wuxi to CBMG Shanghai is convertible into equity interest of CBMG Shanghai and the business cooperation agreement grants the Company and its officers the power to manage and make decisions that affect the operation of CBMG Shanghai.

	There are substantial uncertainties regarding the interpretation, application and enforcement of PRC laws and regulations, including but not limited to the laws and regulations governing our business or the enforcement and performance of our contractual arrangements. See Risk Factors below regarding “Risks Related to Our Structure”. The Company has not provided any guarantees related to CBMG Shanghai and no creditors of CBMG Shanghai have recourse to the general credit of the Company.

	As the primary beneficiary of CBMG Shanghai, the Company consolidates in its financial statements the financial position, results of operations, and cash flows of CBMG Shanghai, and all intercompany balances and transactions between the Company and CBMG Shanghai are eliminated in the consolidated financial statements.

	The Company has aggregated the financial information of CBMG Shanghai in the table below. The aggregate carrying value of CBMG Shanghai’s assets and liabilities (after elimination of intercompany transactions and balances) in the Company’s consolidated balance sheets as of December 31, 2014 and 2013 are as follows:

		December 31,		December 31,
		2014		2013
	Assets
	Cash	$	3,496,678	$	9,100
	Accounts receivable		141,029		-
	Other receivable		127,280		50,383
	Inventory		215,152		26,526
	Prepaid expenses		193,613		33,015
	Other current assets		109,777		84,661
	Total current assets		4,283,529		203,685

	Property, plant and equipment, net		1,055,648		772,872
	Intangibles		42,779		54,793
	Long-term prepaid expenses and other assets		126,503		-
	Total assets	$	5,508,459	$	1,031,350

	Liabilities
	Liabilities:
	Accounts payable	$	10,572	$	24,868
	Other payable		714,309		268,301
	Payroll accrual		273,599		74,384
	Tax payable		-		20,150
	Total current liabilities	$	998,480	$	387,703

	Other non-current liabilities		436,346		-
	Total liabilities	$	1,434,826	$	387,703

7_OTHER_CURRENT_ASSETS

7. OTHER CURRENT ASSETS	12 Months Ended
7. OTHER CURRENT ASSETS	Dec. 31, 2014
Notes to Financial Statements
7. OTHER CURRENT ASSETS	Other Receivables

	The Company pays deposits on various items relating to office expenses. Management has classified these deposits as receivables as the intention is to recover these deposits in less than 12 months. As of December 31, 2014 and 2013 the amounts of other receivables was $135,957 and $78,521, respectively.

8_INVENTORY

8. INVENTORY	12 Months Ended
8. INVENTORY	Dec. 31, 2014
Notes to Financial Statements
8. INVENTORY	At December 31, 2014 and 2013, inventory consisted of the following:

		31-Dec-14		31-Dec-13
	Raw materials	$	128,665	$	27,979
	Work in progress		89,164		-
	Finished goods		154,420		91,140
		$	372,249	$	119,119

9_PROPERTY_PLANT_AND_EQUIPMENT

9. PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
9. PROPERTY, PLANT AND EQUIPMENT	Dec. 31, 2014
Notes to Financial Statements
9. PROPERTY, PLANT AND EQUIPMENT	As of December 31, 2014 and 2013, property, plant and equipment, carried at cost, consisted of the following:

		31-Dec-14			31-Dec-13

	Office equipment	$	16,842		$	17,100
	Manufacturing equipment		1,518,718			775,449
	Computer equipment		73,888			38,147
	Leasehold improvements		1,414,475			1,049,889
	Construction work in process		-			18,645
			3,023,923			1,899,230
	Less: accumulated depreciation		(1,743,513	)		(884,425	)
		$	1,280,410		$	1,014,805

	Depreciation expense for the years ended December 31, 2014, and 2013 was $586,679 and $495,029 respectively.

10_INVESTMENTS

10. INVESTMENTS	12 Months Ended
10. INVESTMENTS	Dec. 31, 2014
Schedule of Investments [Abstract]
10. INVESTMENTS	Assets measured at fair value on a recurring basis as of December 31, 2014 and 2013 are summarized as follows:



	31-Dec-14	Cost		Gross Unrealized Gains		Gross Unrealized Losses more than 12 months		Gross Unrealized Losses less than 12 months			Market or Fair Value
	Equity position in Alpha Lujo, Inc.	$	251,388	$	42,846	$	-	$	-		$	294,234
	Equity position in Arem Pacific Corporation		5,030,000		1,370,000		-		-			6,400,000
	Equity position in Wonder International Education & Investment Group Corporation		191,799		-		-		-			191,799
	Total	$	5,473,187	$	1,412,846	$	-	$	-		$	6,886,033


	31-Dec-13	Cost		Gross Unrealized Gains		Gross Unrealized Losses more than 12 months		Gross Unrealized Losses less than 12 months			Market or Fair Value
	Equity position in Alpha Lujo, Inc.	$	171,388	$	-	$	-	$	(64,270	)	$	107,118
	Equity position in Arem Pacific Corporation		3,500,000		-		-		-			3,500,000
	Equity position in Wonder International Education & Investment Group Corporation		1,627,239		-		-		(128,466	)		1,498,773
	Total	$	5,298,628	$	-	$	-	$	(192,736	)	$	5,105,891


	The Company tracks each investment with an unrealized loss and evaluate them on an individual basis for other-than-temporary impairments, including obtaining corroborating opinions from third party sources, performing trend analysis and reviewing management’s future plans. When investments have declines determined by management to be other-than-temporary the Company recognizes write downs through earnings. Impairment of investments expense for the year ended December 31, 2014 was $1,427,840. No such expense existed for the year ended December 31, 2013.

11_FAIR_VALUE_ACCOUNTING

11. FAIR VALUE ACCOUNTING	12 Months Ended
11. FAIR VALUE ACCOUNTING	Dec. 31, 2014
Notes to Financial Statements
11. FAIR VALUE ACCOUNTING	Assets measured at fair value on a recurring basis as of December 31, 2014 and 2013 are summarized as follows:

		As of December 31, 2014
		Fair Value Measurements at Reporting Date Using:
				Quoted Prices in		Significant Other		Significant
				Active Markets for		Observable		Unobservable
				Identical Assets		Inputs		Inputs
		Total		(Level 1)		(Level 2)		(Level 3)
	Assets:
	Equity position in Alpha Lujo, Inc.	$	294,234	$	-	$	294,234	$	-
	Equity position in Arem Pacific Corporation		6,400,000		-		6,400,000		-
	Equity position in Wonder International Education & Investment Group Corporation		191,799		-		191,799		-
		$	6,886,033	$	-	$	6,886,033	$	-

		As of December 31, 2013
		Fair Vaue Measurements at Reporting Date Using:
				Quoted Prices in		Significant Other		Significant
				Active Markets for		Observable		Unobservable
				Identical Assets		Inputs		Inputs
		Total		(Level 1)		(Level 2)		(Level 3)
	Assets:
	Equity position in Alpha Lujo, Inc.	$	107,118	$	-	$	107,118	$	-
	Equity position in Arem Pacific Corporation		3,500,000		-		3,500,000		-
	Equity position in Wonder International Education & Investment Group Corporation		1,498,773		-		1,498,773		-
		$	5,105,891	$	-	$	5,105,891	$	-

	During the years ended December 31, 2014 and 2013, the Company received and continues to hold 3,000,000 and 5,000,000 respectively, shares of Arem Pacific Corporation as compensation for services performed by the Company's Consulting Segment. As of December 31, 2014 and 2013, the Company holds 2,942,350 and 2,142,350 respectively, shares in Alpha Lujo, Inc. and 2,131,105 and 2,141,105 shares in Wonder International Education and Investment Group Corporation, respectively. All available-for-sale investments held by the Company at December 31, 2014 and 2013 have been valued based on level 2 inputs. Available-for-sale securities classified within level 2 of the fair value hierarchy are valued utilizing pricing reports from independent third party pricing service.

	Due to the limited trading and non-reporting of all three of these companies, we have reclassified these assets to be a level 2 fair value valuation as of December 31, 2014 and 2013.

12_INTANGIBLE_ASSETS

12. INTANGIBLE ASSETS	12 Months Ended
12. INTANGIBLE ASSETS	Dec. 31, 2014
Notes to Financial Statements
12. INTANGIBLE ASSETS	Intangible assets that are subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable. Assets not subject to amortization are tested for impairment at least annually. The Company evaluates the continuing value of the intangibles at each balance sheet date and records write-downs if the continuing value has become impaired. An impairment is determined to exist if the anticipated undiscounted future cash flow attributable to the asset is less than its carrying value. The asset is then reduced to the net present value of the anticipated future cash flow.

	As of December 31, 2014 and 2013, intangible assets, consisted of the following:

	Patents
		31-Dec-14			31-Dec-13
	Cost basis	$	11,404,730		$	1,020,577
	Less: accumulated amortization		(289,758	)		(475,381	)
		$	11,114,972		$	545,196

	Software
		31-Dec-14			31-Dec-13
	Cost basis	$	65,848		$	57,031
	Less: accumulated amortization		(24,144	)		(12,479	)
		$	41,704		$	44,552

	Trademark
		31-Dec-14			31-Dec-13
	Cost basis	$	-		$	11,708
	Less: accumulated amortization		-			-
		$	-		$	11,708

	Total intangibles, net	$	11,156,676		$	601,456

	All software is provided by a third party vendor, is not internally developed, and has an estimated useful life of 5 years. Patents are amortized using an estimated useful life of 5 to 10 years. Amortization expense for the years ended December 31, 2014 and 2013 was $603,826 and $346,206, respectively. Estimated amortization expense for each of the ensuing years are as follows for the years ending December 31:

	Years ending December 31,	Amount
	2015	$	1,156,133
	2016		1,156,133
	2017		1,156,133
	2018		1,150,437
	2019 and thereafter		6,537,840
		$	11,156,676

13_LEASES

13. LEASES	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
13. LEASES	The Company leases facilities under non-cancellable operating lease agreements. These facilities are located in the United States, Hong Kong and China. The Company recognizes rent expense on a straight-line basis over the life of the lease period. Rent expense under operating leases for the years ended December 31, 2014 and 2013 was approximately $576,000 and $454,000, respectively.

	As of December 31, 2014, the Company has the following future minimum lease payments due under the foregoing lease agreements:

	Years ending December 31,	Amount
	2015	$	711,153
	2016		515,654
		$	1,226,807

14_RELATED_PARTY_TRANSACTIONS

14. RELATED PARTY TRANSACTIONS	12 Months Ended
14. RELATED PARTY TRANSACTIONS	Dec. 31, 2014
Notes to Financial Statements
14. RELATED PARTY TRANSACTIONS	The net balance due to related parties is $36,254 as of December 31, 2014, representing $6,037 for combined advances from the Company’s executives and $30,217 to a subsidiary of Global Health Investment Holdings Ltd. (“Global Health”). Prior to August 26, 2014, Global Health was the Company’s largest shareholder. On August 26, 2014 Global Health Investment Holdings Ltd. disseminated its CBMG shareholdings, on a pro rata basis, to its shareholders. The net balance due to related parties was $67,999 as of December 31, 2013, representing $37,784 for combined advances from the Company’s executives and $30,215 to a subsidiary of Global Health, CBMG’s largest shareholder.

	The Company received income from the Subsidiaries of Global Health for cell kits with cell processing and storage for the year ended December 31, 2014 and 2013, of approximately $179,000 and $204,900, respectively.

	During the year ended December 31, 2013, the Company paid $1,493,439 to the executives of its consulting segment subsidiary, Eastbridge Sub, to settle all outstanding accrued compensation liabilities, no such settlement of accrued compensation existed for the year ended December 31, 2014.

15_EQUITY

15. EQUITY	12 Months Ended
15. EQUITY	Dec. 31, 2014
Notes to Financial Statements
15. EQUITY	ASC Topic 505 Equity paragraph 505-50-30-6 establishes that share-based payment transactions with nonemployees shall be measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.

	In March 2014, the Company entered into several Subscription Agreements with selected investors (the “Purchasers”) that met the criteria as “Accredited Investors” as defined in Rule 501(a) of Regulation D under the Securities Act of 1933 (the “Act”), and other investors who met the criteria as “non-U.S. persons” who agreed to comply with the applicable requirements of Regulation S under the Act. As a result of these transactions, the Company issued to the purchasers an aggregate of 194,029 shares of common stock, at a price per share of $6.70 for an aggregate purchase price of approximately $1,220,000.

	In June 2014, the Company entered into several Subscription Agreements with selected investors that met the criteria as “non-U.S. persons” who agreed to comply with the applicable requirements of Regulation S under the Act. As a result of these transactions, the Company issued to the purchasers an aggregate of 1,492,537 shares of common stock, at a price per share of $6.70 for an aggregate purchase price of approximately $10,000,000. Certain warrants were issued to the placement agent in this offering. These warrants were all exercised in the year ended December 31, 2014 and 17,765 shares of common stock were issued.

	The Company issued to the lead investor in the June 2014 financing, a three-year option to purchase up to 1,000,000 shares of common stock at $8.00 per share. Pursuant to the terms of the option, if at any time after 18 months following the date of issuance, the daily volume-weighted average price of the Company’s common stock exceeds $12.00 for a consecutive 20 trading days, the Company shall have the right to require the holder to exercise the option in full. In December 2014, the Company received approximately $8,000,000 as this agreement was exercised fully.

	In September 2014, the Company entered into several agreements with selected parties for the purchase of Agreen and patents as described in Note 4. As a result of these transactions, the Company issued an aggregate of 828,522 shares of common stock, at a price per share of $19.238 for an aggregate price of approximately $15,939,000.

	In December 2014, the Company issued 39,260 shares as a finder fee to the Agreen acquisition. In connection with this issuance the Company recorded expense of approximately $480,000. The share price on the date of this signed agreement was $12.22 and was used to calculate number of shares to issue.

	During the year ended December 31, 2014, the Company issued 13,413 shares of common stock, to officers of the Company for services rendered. The Company expensed $207,201 in connection with these issuances based on the quoted market prices on the dates of issuance.

	During the years ended December 31, 2014 and 2013, the Company expensed $1,742,703 and $792,645, respectively, associate with unvested restricted and option awards that generally vest over a three year period.

	Immediately prior to the reverse merger the Company had 1,570,299 shares outstanding. The Company issued 3,638,941 shares in connection with the merger. See Note 1 for a discussion of the accounting for the merger.

	During the year ended December 31, 2013, the Company issued 231,384 shares of common stock to third parties for services rendered. The Company expensed $1,157,099 in connection with these issuances based on the quoted market prices on the dates of issuance.

	During the year ended December 31, 2013, the Company issued 65,000 shares of common stock, to the former officers and employee of the Company. The Company expensed $386,250 in connection with these issuances based on the quoted market prices on the dates of issuance

	During the year ended December 31, 2013, the Company issued 71,814 shares of common stock to employees that had earned these shares as compensation as of the date of merger. The Company expensed $350,402 in connection with these issuances based on the quoted market prices on the dates of issuance.

	During year ended December 31, 2013, the Company issued 342,360 shares of common stock to specific stockholders as the Company did not achieve ten Phase II clinical trials by March 31, 2013 in accordance with the terms and conditions of certain private placement agreements entered into by private investors in CBMG BVI and assumed by the Company. The Company expensed $1,694,682 in connection with these issuances based on the quoted market prices on the dates of issuance. There are no further milestones that would require additional stock issuances.

	On July 24, 2013, the Company entered into a Subscription Agreement with selected investors that met the criteria as “Accredited Investors” as defined in Rule 501(a) of Regulation D under the Securities Act of 1933, and other investors who met the criteria as “non-U.S. persons” who agreed to comply with the applicable requirements of Regulation S under the Act. The Company offered to sell up to an aggregate of 1,194,030 shares of the Company’s common stock. During the three months ended September 30, 2013, the Company issued to the Purchasers an aggregate of 597,763 shares of common stock at a price per share of $6.70 for an aggregate purchase price of $4,005,072.

	On December 13, 2013, the Company entered into several Subscription Agreements with selected investors that met the criteria as “Accredited Investors” as defined in Rule 501(a) of Regulation D under the Securities Act of 1933, and other investors who met the criteria as “non-U.S. persons” who agreed to comply with the applicable requirements of Regulation S under the Act. As a result of these transactions, the Company issued to the Purchasers an aggregate of 837,105 shares of common stock, at a price per share of $6.70 for an aggregate purchase price of $5,608,024.

16_COMMITMENTS_AND_CONTINGENCI

16. COMMITMENTS AND CONTINGENCIES	12 Months Ended
16. COMMITMENTS AND CONTINGENCIES	Dec. 31, 2014
Notes to Financial Statements
16. COMMITMENTS AND CONTINGENCIES	Executive Employment Agreements

	At the close of the merger with CBMG BVI, the Company entered into executive employment agreements with each of Wen Tao (Steve) Liu, Wei (William) Cao and Andrew Chan (the “New Officers”) dated February 6, 2013 (each an “Employment Agreement,” collectively, the “Employment Agreements”). Pursuant to Amendment 1 to the Employment Agreement, Andrew Chan will receive an annual base salary of $200,000. Pursuant to Board of Directors (“BOD”) Minutes dated September 29, 2013, Steve Liu and William Cao will receive an annual base salary of $200,000 and $225,000, respectively. The New Officers are also eligible to participate in the Company’s Amended and Restated 2011 Incentive Stock Option Plan (the “2011 Plan”) and receive an option grant thereunder for the purchase of common stock of the Company at the discretion of the board of directors of the Company (the “Board”). The term of the New Officers’ employment agreements are effective as of February 6, 2013 and continue for three years thereafter. After the three year term, if the New Officers continue to be employed, they will be employed on an at-will basis and their agreements shall automatically renew for successive one year terms, until and unless their employment is terminated.

	Each of the above Executive Employment Agreements contain termination provisions that dependent on the reason an executive is terminated, severance payments and the payment of COBRA premiums may be triggered.

	On January 3, 2014 the Company entered into an executive employment agreement with Bizuo (Tony) Liu (the "Liu Employment Agreement"). Pursuant to the Liu Employment Agreement, Tony Liu will receive an annual base salary of $210,000 with substantially similar terms and conditions as the New Officers.

	On May 1, 2014 the Company revised Wen Tao (Steve) Liu’s agreement (the “Wen Tao Employment Agreement”). Pursuant to the Wen Tao Employment Agreement, Steve Liu will receive an annual base salary of $150,000 as part-time Executive Chairman.

	Discontinued Operations Plan

	Effective July 31, 2014, in connection with the Company’s discontinuation of its consulting business, the Company terminated the Subsidiary Employment Agreements with Messrs. Klein and Wong. On the same date, the Company entered into severance agreements with Messrs. Klein and Wong. Pursuant to the terms of the severance agreements, the Company agreed to pay severance of $360,000 and $480,000 to Messrs. Klein and Wong, respectively, as well as an additional lump sum of $4,200 and $12,480, respectively, to cover the equivalent costs of retaining two years of medical coverage under the Company’s current medical plan for such individuals.

	Deferred Compensation Arrangement with Former Officers

	On February 5, 2013, the Company entered into a Deferred Compensation Agreement with Keith Wong and Norman Klein (the “Former Executives”), in which the Company agreed to: (i) pay its Former Executives certain accrued unpaid cash compensation consisting of $676,839 payable to Keith Wong and $459,300 payable to Norman Klein, plus aggregate accrued interest calculated at the simple rate of 12% per annum; and (ii) pay on August 31, 2013, a cash bonus payment of $204,723 to Mr. Wong and $152,577 to Mr. Klein. As of September 30, 2013, all such amounts were paid. A copy of the Deferred Compensation Agreement was attached as Exhibit 10.9 to our current report on Form 8-K filed February 12, 2013.

	Collaboration Agreement

	Part of AG’s business (see Note 4) includes a collaboration agreement to establish and operate a biologic treatment center in the Jilin province of China. Under the terms of the agreement, AG’s collaborative partner funded the development of the center and provides certain ongoing services. In exchange, the partner receives preferred repayment of all funds that were invested in the development, 60% of the net profits until all of the invested funds are repaid, and 40% of the net profits thereafter, and the rights to the physical assets at the conclusion of the agreement. We are accounting for this transaction in accordance with ASC 808 Collaborative Arrangements and have reflected all assets and liabilities of the treatment center. While a liability exists for the amounts to be repaid to the partner for the initial funding, no liability has been recognized for the partner’s rights to the assets upon the conclusion of the agreement as there is no specified termination date to the agreement.

17_STOCK_BASED_COMPENSATION

17. STOCK BASED COMPENSATION	12 Months Ended
17. STOCK BASED COMPENSATION	Dec. 31, 2014
Notes to Financial Statements
17. STOCK BASED COMPENSATION	Our stock-based compensation arrangements include grants of stock options and restricted stock awards under the Stock Option Plan (the “2009 Plan”,“2011 Plan”, and the “2013 Plan”), and certain awards granted outside of these plans. The compensation cost that has been charged against income related to stock-based compensation (including shares issued for services and expense true-ups and reversals described in Note 15) for the years ended December 31, 2014 and 2013 was $1,949,904 and $1,529,297, respectively, and is included in general and administrative expense in our Consolidated Statements of Operations. As of December 31, 2014, there was $7,642,709 all unrecognized compensation cost related to an aggregate of 1,048,961 of non-vested stock option awards and $97,748 related to an aggregate of 7,115 of non-vested restricted stock awards. These costs are expected to be recognized over a weighted-average period of 1.84 years for the stock options awards and 0.8 years for the restricted stock awards.

	During the year ended December 31, 2014, the Company issued options under the 2011 and 2013 Plans to purchase an aggregate of 795,500 shares of the Company’s common stock to officers, directors and employees. The grant date fair value of these options was $6,884,822 using Black-Scholes option valuation models with the following assumptions: exercise price equal to the grant date stock price of $5.00 to $28.49, volatility 112% to 130%, expected life 6.0 years, and risk-free rate of 1.77% to 2.08%. The Company is expensing these options on a straight-line basis over the requisite service period.

	The following table summarizes stock option activity as of December 31, 2014 and 2013:

		Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value

	Outstanding at December 31, 2013		705,073		$	4.19		9.2	$	735,132
	Grants		795,500			10.53
	Forfeitures		(71,750	)		5.06
	Exercises		(3,650	)		5.31
	Outstanding at December 31, 2014		1,425,173		$	7.37		8.9	$	11,065,770

	Vested and exercisable at December 31, 2014		376,212		$	4.18		8.5	$	3,730,238

		Exercise			Number of Options
		Price			Outstanding		Exercisable

		$3.00 - $4.95				350,883		153,662
		$5.00 - $9.19				810,990		222,550
		$14.50+				263,300		-
						1,425,173		376,212

	The aggregate intrinsic value for stock options outstanding and exercisable is defined as the positive difference between the fair market value of our common stock and the exercise price of the stock options. As of December 31, 2014, we expect to recognize approximately $7,640,000 of stock-based compensation for our outstanding options over a weighted-average period of 1.7 years.

	Cash received from option exercises under all share-based payment arrangements for the year ended December 31, 2014 was $19,387. No options were exercised in 2013.

18_NET_INCOME_LOSS_PER_SHARE

18. NET INCOME (LOSS) PER SHARE	12 Months Ended
18. NET INCOME (LOSS) PER SHARE	Dec. 31, 2014
Notes to Financial Statements
18. NET INCOME (LOSS) PER SHARE	Basic and diluted net loss per common share is computed on the basis of our weighted average number of common shares outstanding, as determined by using the calculations outlined below:

		For the Year Ended
		December 31,
		2014			2013

	Loss from continuing operations	$	(12,355,459	)	$	(11,358,519	)

	Loss on discontinued operations	$	(3,119,152	)	$	(2,438,514	)

	Net loss	$	(15,474,611	)	$	(13,797,033	)

	Weighted average shares of common stock		8,627,094			5,792,888
	Dilutive effect of stock options		-			-
	Restricted stock vested not issued		-			-
	Common stock and common stock equivalents		8,627,094			5,792,888

	Loss from continuing operations per basic share	$	(1.43	)	$	(1.96	)
	Loss from continuing operations per diluted share	$	(1.43	)	$	(1.96	)

	Loss on discontinued operations per basic share	$	(0.36	)	$	(0.42	)
	Loss on discontinued operations per diluted share	$	(0.36	)	$	(0.42	)

	Net loss per basic share	$	(1.79	)	$	(2.38	)
	Net loss per diluted share	$	(1.79	)	$	(2.38	)

	The calculation of diluted net income per common share excludes the effects of 590,545 outstanding stock options for the year ended December 31, 2014 as the impact of these options was anti-dilutive. There were 2,310 anti-dilutive share equivalents for the year ended December 31, 2013.

19_INCOME_TAXES

19. INCOME TAXES	12 Months Ended
19. INCOME TAXES	Dec. 31, 2014
Notes to Financial Statements
19. INCOME TAXES	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period during which such rates are enacted.

	The Company considers all available evidence to determine whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become realizable. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carry-forward periods), and projected taxable income in assessing the realizability of deferred tax assets. In making such judgments, significant weight is given to evidence that can be objectively verified. Based on all available evidence, in particular our three-year historical cumulative losses, recent operating losses and U.S. pre-tax loss for the fiscal year ending December 31, 2014, we recorded a valuation allowance against our U.S. net deferred tax assets. In order to fully realize the U.S. deferred tax assets, we will need to generate sufficient taxable income in future periods before the expiration of the deferred tax assets governed by the tax code.

	The following represent components of the current tax expense for the year ended December 31, 2014 and 2013.

		December 31,			December 31,
		2014			2013
	Current tax expense:
	US federal	$	41,798		$	339,856
	US state		8,947			4,590
		$	50,745		$	344,446

	The following represent components of net deferred tax assets at December 31, 2014 and 2013:

		December 31,			December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carry forwards (offshore)	$	4,343,930		$	2,811,207
	Net operating loss carry forwards (US)		1,823,432			-
	Accrued compensation (US)		581,129			294,127
	Stock options (US)		1,217,927			1,909,635
	Investments (US)		599,332			-

	Deferred tax liabilities		-			-

	Subtotal		8,565,750			5,014,969
	Less: valuation allowance		(8,565,750	)		(5,014,969	)
	Net deferred tax asset	$	-		$	-

	In each period since inception, the Company has recorded a valuation allowance for the full amount of net deferred tax assets, as the realization of deferred tax assets is uncertain. As a result, the Company has not recorded any federal or state income tax benefit in the consolidated statements of operations and comprehensive income (loss).

	As of December 31, 2014, the Company had net operating loss carryforwards of $4.3 million for U.S federal purposes, $4.3 million for U.S. state purposes, and $17.4 million for Chinese income tax purposes such losses are set to expire in 2034, 2034, and 2019 for U.S. federal, U.S. state and Chinese income tax purposes, respectively. All deferred income tax expense is offset by changes in the valuation allowance pertaining to the Company's existing net operating loss carryforwards. The Company's effective tax rate differs from statutory rates of 35% for U.S. federal income tax purposes and 25% for Chinese income tax purposes due to the effects of the valuation allowance and certain permanent differences as it pertains to book-tax differences in the value of client shares received for services.

	The following table summarizes a reconciliation of Income tax expense (benefit) for the year ended December 31, 2014 compared with the amounts at the U.S. federal statutory rate:

	Effective Tax Rate Reconciliation
	Federal tax		(35.00	)%
	State tax		0.04	%
	Goodwill impairment		7.49	%
	Foreign tax rate difference		13.91	%
	Other permanent difference		0.29	%
	Change in valuation allowance		13.59	%

	Provisional rate		0.32	%

	Under Section 382 of the Code, substantial changes in ownership may limit the amount of NOLs that can be utilized annually in the future to offset taxable income, if any. Specifically, this limitation may arise in the event of a cumulative change in ownership of more than 50% within a three-year period as determined under the Code. Any such annual limitation may significantly reduce the utilization of these NOLs before they expire. The Company’s ability to utilize federal NOLs created prior to the merger is significantly limited. Prior to the merger, CBMG Ltd. had completed a partial analysis of ownership changes under Section 382 of the Code to determine if a change in control had occurred. Based on this partial analysis, no change in control was identified. A complete formal analysis of ownership change would have to be performed in order to obtain certainty that a change in control had not occurred prior to the merger, which could further limit the utilization of pre-merger NOLs.

20_SUBSEQUENT_EVENTS

20. SUBSEQUENT EVENTS	12 Months Ended
20. SUBSEQUENT EVENTS	Dec. 31, 2014
Subsequent Events [Abstract]
20. SUBSEQUENT EVENTS	On February 4, 2015, Cellular Biomedicine Group Ltd. (Shanghai) (“CBMG”), an operating subsidiary of Cellular Biomedicine Group Inc. (the “Company”), entered into a technology transfer agreement (the “Transfer Agreement”) with the Chinese PLA General Hospital PLAGH (also known as “301 Hospital”).

	Pursuant to the terms of the Transfer Agreement, PLAGH agreed to transfer to CBMG all of its right, title and interest in and to certain technologies currently owned by PLAGH (including, without limitation, four technologies and their pending patent applications) that relate to genetic engineering of chimeric antigen receptor (CAR)-modified T cells and its applications (collectively, the “Technology”). In addition, PLAGH is responsible for obtaining governmental approval for the clinical trial related to the Technology, and CBMG (Shanghai) is responsible for the costs and expenses in connection therewith.

	In consideration for the Technology, CBMG agreed to pay to PLAGH the following: (i) RMB 3.2 million (approximately $512,000) within 5 business days following the date of the Transfer Agreement, (ii) RMB 6.8 million (approximately $1,109,000) within 5 business days following delivery by PLAGH to CBMG all the materials and documents related to the Technology, and (iii) RMB 2 million (approximately $320,000) within 5 business days following execution of clinical cooperation agreement between CBMG and PLAGH. The Transfer Agreement contains customary confidentiality and event of default provisions.

	In March 2015, the Company initiated a financing transaction pursuant to which it would sell up to 526,316 shares of the Company’s common stock, to selected investors at $38 per share, for total gross proceeds of approximately $20,000,000. The Shares were sold pursuant to separate subscription agreements between the Company and each Investor. Up to the issuance of the financial statements, $20,000,000 (unaudited) were received from investors.

3_SUMMARY_OF_SIGNIFICANT_ACCOU1

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies Policies
Principles of Consolidation	Principles of Consolidation

	The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, or GAAP, and reflect the accounts and operations of the Company and its majority or wholly-owned subsidiaries, beginning with the date of their respective acquisition. In accordance with the provisions of Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) Section 810, or ASC 810, Consolidation, the Company consolidates any variable interest entity, or VIE, of which it is the primary beneficiary. The typical condition for a controlling financial interest ownership is holding a majority of the voting interests of an entity; however, a controlling financial interest may also exist in entities, such as variable interest entities, through arrangements that do not involve controlling voting interests. ASC 810 requires a variable interest holder to consolidate a VIE if that party has the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance, and the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company does not consolidate a VIE in which it has a majority ownership interest when the Company is not considered the primary beneficiary. The Company has determined that it is the primary beneficiary in a VIE—refer to Note 6, Variable Interest Entity. The Company evaluates its relationships with the VIE on an ongoing basis to ensure that it continues to be the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	Use of Estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements.

	These estimates and assumptions also affect the reported amounts of revenues, costs and expenses during the reporting period. Management evaluates these estimates and assumptions on a regular basis. Actual results could materially differ from those estimates.
Revenue Recognition	Revenue Recognition

	The Company utilizes the guidance set forth in the Securities and Exchange Commission's Staff Accounting Bulletin (SAB) No. 104, regarding the recognition, presentation and disclosure of revenue in its financial statements.

	For its Consulting segment, the Company engaged in listing contracts with its clients which provide for the payment of fees, either in cash or equity, upon the achievement of certain milestones by the client, including the successful completion of a financial statement audit, the successful listing on a national stock exchange or over-the-counter market and the maintenance of ongoing 1934 Act reporting requirements with the Securities and Exchange Commission. In some instances, payment may be made in advance of performance; however, such payment was often refundable in the event that milestones were not reached. The Company recognized revenue as milestones are reached in accordance with FASB’s Accounting Standards Codification (ASC) No. 605-28-25. Such guidance stipulates that revenue be recognized for individual elements in a multiple deliverable arrangement using the relative selling price method. The Company relied on internal estimates of the relative selling price of each element as objective third-party evidence is unattainable. This segment was discontinued in 2014 and will not have further revenue.

	For its Biomedicine segment, the Company recognizes revenue when pervasive evidence of an arrangement exists, the price is fixed and determinable, collection is reasonably assured and delivery of products or services has been rendered. The Biomedicine segment has started to generate revenues with the acquisition of AG and expects to expand revenue generating activities significantly over the next two to five years as additional therapies are developed.
Cash and Cash Equivalents	Cash and Cash Equivalents

	The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At December 31, 2014 and 2013, respectively, cash and cash equivalents include cash on hand and cash in the bank. At times, cash deposits may exceed government-insured limits.
Accounts Receivable	Accounts Receivable

	Accounts receivable represent amounts earned but not collected in connection with the Company’s sales as of December 31, 2014 and 2013. Accounts receivable are carried at their estimated collectible amounts.

	The Company follows the allowance method of recognizing uncollectible accounts receivable. The Company recognizes bad debt expense based on specifically identified customers and invoices that are anticipated to be uncollectable. At December 31, 2014 and December 31, 2013, an allowance was determined to not be needed as the Company has recently started generating revenues from its cell therapy treatments in the Biomedicine segment in 2014. Correspondingly the Company has not recorded any bad debt expense for the periods ended December 31, 2014 and 2013, respectively.
Inventory	Inventory

	Inventories consist of finished goods, raw materials, work-in-process, and low value consumable materials. Inventories are initially recognized at cost and subsequently at the lower of cost and net realizable value under first-in first-out method. Finished goods are comprised of direct materials, direct labor, depreciation and manufacturing overhead. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose. The Company regularly inspects the shelf life of prepared finished goods and, if necessary, writes down their carrying value based on their salability and expiration dates into cost of goods sold.
Property, Plant and Equipment	Property, Plant and Equipment

	Property, plant and equipment are recorded at cost. Depreciation is provided for on the straight-line method over the estimated useful lives of the assets ranging from three to ten years and begins when the related assets are placed in service. Maintenance and repairs that neither materially add to the value of the property nor appreciably prolong its life are charged to expense as incurred. Betterments or renewals are capitalized when incurred. Plant, property and equipment are reviewed each year to determine whether any events or circumstances indicate that the carrying amount of the assets may not be recoverable. We assess the recoverability of the asset by comparing the projected undiscounted net cash flows associated with the related assets over the estimated remaining life against the respective carrying value.

	For the years ended December 31, 2014 and 2013, depreciation expense was $586,679 and $495,029, respectively.
Goodwill and Other Intangibles	Goodwill and Other Intangibles

	Goodwill represents the excess of the cost of assets acquired over the fair value of the net assets at the date of acquisition. Intangible assets represent the fair value of separately recognizable intangible assets acquired in connection with the Company’s business combinations. The Company evaluates its goodwill and other intangibles for impairment on an annual basis or whenever events or circumstances indicate that an impairment may have occurred. As part of the determination to discontinue the Consulting segment, in the second quarter of 2014, the Company expensed approximately $3,300,000 which represented the remaining goodwill from the 2013 merger. In December, 2013 the Company determined that the goodwill was impaired and therefore recorded impairment expense of $4,258,967.
Income Taxes	Income Taxes

	Income taxes are accounted for using the asset and liability method. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance would be provided for those deferred tax assets if it is more likely than not that the related benefit will not be realized.

	A full valuation allowance has been established against all net deferred tax assets as of December 31, 2014 and 2013 based on estimates of recoverability. While the Company has optimistic plans for its business strategy, we determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to the Company’s ability to generate sufficient profits from its business model.
Share-Based Compensation	Share-Based Compensation

	The Company periodically uses stock-based awards, consisting of shares of common stock and stock options, to compensate certain officers and consultants. Shares are expensed on a straight line basis over the requisite service period based on the grant date fair value, net of estimated forfeitures, if any. We currently use the Black-Scholes option-pricing model to estimate the fair value of our stock-based payment awards. This model requires the input of highly subjective assumptions, including the fair value of the underlying common stock, the expected volatility of the price of our common stock, risk-free interest rates, the expected term of the option and the expected dividend yield of our common stock. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. These assumptions are estimated as follows:

	●	Fair Value of Our Common Stock — Our common stock is valued by reference to the publicly-traded price of our common stock.

	●	Expected Volatility — Prior to the Eastbridge merger, we did not have a history of market prices for our common stock and since the merger, we do not have what we consider a sufficiently active and readily traded market for our common stock to use historical market prices for our common stock to estimate volatility. Accordingly, we estimate the expected stock price volatility for our common stock by taking the median historical stock price volatility for industry peers based on daily price observations over a period equivalent to the expected term of the stock option grants. Industry peers consist of other public companies in the stem cell industry similar in size, stage of life cycle and financial leverage. We intend to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of our own common stock share price becomes available.

	●	Risk-Free Interest Rate — The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of our awards. The risk-free interest rate assumption is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options for each option group.

	●	Expected Term — The expected term represents the period that our stock-based awards are expected to be outstanding. The expected terms of the awards are based on a simplified method which defines the life as the average of the contractual term of the options and the weighted-average vesting period for all open tranches.

	●	Expected Dividend Yield — We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. Consequently, we used an expected dividend yield of zero.

	In addition to the assumptions used in the Black-Scholes option-pricing model, the amount of stock option expense we recognize in our consolidated statements of operations includes an estimate of stock option forfeitures. We estimate our forfeiture rate based on an analysis of our actual forfeitures and will continue to evaluate the appropriateness of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover and other factors. Changes in the estimated forfeiture rate can have a significant impact on our stock-based compensation expense as the cumulative effect of adjusting the rate is recognized in the period the forfeiture estimate is changed. If a revised forfeiture rate is higher than the previously estimated forfeiture rate, an adjustment is made that will result in a decrease to the stock-based compensation expense recognized in the consolidated financial statements. If a revised forfeiture rate is lower than the previously estimated forfeiture rate, an adjustment is made that will result in an increase to the stock-based compensation expense recognized in our consolidated financial statements.
Fair Value of Financial Instruments	Fair Value of Financial Instruments

	Under the FASB’s authoritative guidance on fair value measurements, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated or generally unobservable inputs. The Company uses valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based on observability of the inputs used in the valuation techniques, the Company is required to provide the following information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:

	Level 1: Valuations for assets and liabilities traded in active exchange markets. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

	Level 2: Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third party pricing services for identical or similar assets or liabilities.

	Level 3: Valuations for assets and liabilities that are derived from other valuation methodologies, including option pricing models, discounted cash flow models and similar techniques, and not based on market exchange, dealer or broker traded transactions. Level 3 valuations incorporate certain unobservable assumptions and projections in determining the fair value assigned to such assets.

	All transfers between fair value hierarchy levels are recognized by the Company at the end of each reporting period. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an investment’s level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement in its entirety requires judgment, and considers factors specific to the investment. The inputs or methodology used for valuing financial instruments are not necessarily an indication of the risks associated with investment in those instruments.

	The carrying amounts of other financial instruments, including cash, accounts payable and accrued liabilities, income tax payable and related party payable approximate fair value due to their short maturities.
Investments	Investments

	The fair value of “investments” is dependent on the type of investment, whether it is marketable or non-marketable.

	Marketable securities held by the Company are held for an indefinite period of time and thus are classified as available-for-sale securities. The fair value is based on quoted market prices for the investment as of the balance sheet date. Realized investment gains and losses are included in the statement of operations, as are provisions for other than temporary declines in the market value of available for-sale securities. Unrealized gains and unrealized losses deemed to be temporary are excluded from earnings (losses), net of applicable taxes, as a component of other comprehensive income (loss). Factors considered in judging whether an impairment is other than temporary include the financial condition, business prospects and creditworthiness of the issuer, the length of time that fair value has been less than cost, the relative amount of decline, and the Company’s ability and intent to hold the investment until the fair value recovers.

	The carrying amounts of other financial instruments, including cash, accounts payable and accrued liabilities, income tax payable and related party payable approximate fair value due to their short maturities.
Basic and Diluted Net Loss Per Share	Basic and Diluted Net Loss Per Share

	Diluted income (loss) per share reflects potential dilution from the exercise or conversion of securities into common stock. The dilutive effect of the Company's share-based awards is computed using the treasury stock method, which assumes that all share-based awards are exercised and the hypothetical proceeds from exercise are used to purchase common stock at the average market price during the period. Share-based awards whose effects are anti-dilutive are excluded from computing diluted income (loss) per share. Due to the net loss, all common stock equivalents are anti-dilutive for the years ended December 31, 2014 and 2013.
Foreign Currency Translation	Foreign Currency Translation

	The Company's financial statements are presented in U.S. dollars ($), which is the Company’s reporting currency, while some of the Company’s subsidiaries’ functional currency is Chinese Renminbi (RMB). Transactions in foreign currencies are initially recorded at the functional currency rate ruling at the date of transaction. Any differences between the initially recorded amount and the settlement amount are recorded as a gain or loss on foreign currency transaction in the consolidated statements of operations. Monetary assets and liabilities denominated in foreign currency are translated at the functional currency rate of exchange ruling at the balance sheet date. Any differences are recorded as an unrealized gain or loss on foreign currency translation in the statements of operations and comprehensive loss. In accordance with ASC 830, Foreign Currency Matters, the Company translates the assets and liabilities into USD from RMB using the rate of exchange prevailing at the applicable balance sheet date and the statements of income and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation are recorded in shareholders' equity as part of accumulated other comprehensive income. The PRC government imposes significant exchange restrictions on fund transfers out of the PRC that are not related to business operations. These restrictions have not had a material impact on the Company because it has not engaged in any significant transactions that are subject to the restrictions.
Comprehensive Loss	Comprehensive Loss

	We apply ASC No. 220, Comprehensive Income (ASC 220). ASC 220 establishes standards for the reporting and display of comprehensive income or loss, requiring its components to be reported in a financial statement that is displayed with the same prominence as other financial statements. Our comprehensive loss was $13,848,312 and $13,916,583 for the years ended December 31, 2014 and 2013, respectively.
Reclassification	Reclassification

	Certain prior period amounts have been reclassified to conform to current year presentations. There was no change to previously reported stockholders’ deficit or net loss.
Segment Information	Segment Information

	FASB ASC No. 280, “Segment Reporting” establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group in deciding how to allocate resources and in assessing performance. Following the discontinuance of our consulting business, we operate in a single reportable segment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements

	Recent accounting pronouncements that the Company has adopted or may be required to adopt in the future are summarized below.

	In February 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis” (“ASU 2015-02”). The amendments in this update affect reporting entities that are required to evaluate whether they should consolidate certain legal entities. All legal entities are subject to reevaluation under the revised consolidation model. ASU 2015-02 is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-02 on our consolidated financial statements.

	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). The amendments in this update require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. We are currently in the process of evaluating the impact of the adoption of ASU 2014-15 on our consolidated financial statements.

	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in “Revenue Recognition (Topic 605)”, and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early adoption is not permitted. We are currently in the process of evaluating the impact of the adoption of ASU 2014-09 on our consolidated financial statements.

	In April 2014, the FASB issued ASU 2014-08, “Presentation of Financial Statements (Topic205)” and “Property Plant and Equipment (Topic 360)”. The amendments in this ASU modify the requirements for the reporting of discontinued operations. In order to qualify as a discontinued operation, the disposal of a component of an entity, a group of components, or a business of an entity must represent a strategic shift that has (or will have) a major effect on an entity's operations and financial results. The ASU further indicates that the timing for recording a discontinued operation is when one of the following occurs: the component, group of components, or business meets the criteria to be classified as held-for-sale; the component, group of components, or business is disposed of by sale; or the component, group of components, or business is disposed of other than by sale (for example abandonment or spinoff). In addition, the ASU also requires additional disclosure items about an entity's discontinued operations. The amendments are effective for us beginning on January 1, 2015. The amendments are to be applied prospectively solely to newly identified disposals that qualify as discontinued operations after the effective date. Items previously reported as discontinued operations will maintain their classification based on the prior guidance. Early adoption is permitted, but only for disposals that have not been previously reported as discontinued operations in previously issued financial statements. We are currently in the process of evaluating the impact of the adoption of ASU 2014-08 on our consolidated financial statements.

4_BUSINESS_COMBINATION_Tables

4. BUSINESS COMBINATION (Tables)	12 Months Ended
4. BUSINESS COMBINATION (Tables)	Dec. 31, 2014
Business Combination Tables
Final allocation of the purchase price	The following table provides the final allocation of purchase price based on the estimated fair values of the assets acquired (including intangible assets) and liabilities assumed in connection with the acquisition:

	Cash	$	145,611
	Accounts receivable		151,093
	Other receivable		31,798
	Inventory		174,820
	Prepaid expenses		14,331
	Property, plant and equipment, net		561,113
	Intangible assets		9,942,000
	Goodwill		7,678,786
	Long-term prepaid expenses		83,054
	Total assets acquired		18,782,606

	Accounts payables		(47,509	)
	Accrued expenses		(42,013	)
	Other current liabilities		(523,077	)
	Other non current liabilities		(422,592	)
	Total liabilities assumed		(1,035,191	)

	Purchase price	$	17,747,415
Unaudited pro forma consolidated results of operations	The following unaudited pro forma consolidated results of operations has been prepared as if the acquisition of AG and related patents and intellectual property described above had occurred on January 1, 2013 and includes adjustments for the amortization of intangibles and the earnings-per-share impacts of the issuance of shares as part of the acquisition of AG and related patents and intellectual property:

		Year Ended December 31, 2014									Year Ended December 31, 2013
		CBMG			Agreen			Pro forma			CBMG			Agreen			Pro forma
		As stated			Pro forma Adjustment			Consolidated			As stated			Pro forma Adjustment			Consolidated
	Net sales and revenue	$	564,377		$	1,198,414		$	1,762,791		$	204,914		$	1,075,692		$	1,280,606
	Net loss		(15,474,611	)		(48,109	)		(15,522,720	)		(13,797,033	)		(338,804	)		(14,135,837	)

	Weighted average common shares outstanding:
	Basic		8,627,094			555,335			9,182,429			5,792,888			753,522			6,546,410
	Diluted		8,627,094			555,335			9,182,429			5,792,888			753,522			6,546,410
	Earnings (loss) per share net loss:
	Basic	$	(1.79	)	$	(0.09	)	$	(1.69	)	$	(2.38	)	$	(0.45	)	$	(2.16	)
	Diluted	$	(1.79	)	$	(0.09	)	$	(1.69	)	$	(2.38	)	$	(0.45	)	$	(2.16	)

5_DISCONTINUED_OPERATIONS_Tabl

5. DISCONTINUED OPERATIONS (Tables)	12 Months Ended
5. DISCONTINUED OPERATIONS (Tables)	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Assets and liabilities of the discontinued operations	The assets and liabilities of the discontinued operations are presented below under the captions ‘‘Assets of discontinued segment’’ and ‘‘Liabilities of discontinued segment,’’ respectively, in the accompanying Balance Sheets at December 31, 2014 and 2013, respectively, and consist of the following:

		December			December 31,
		2014			2013
	Assets of discontinued segment:

	Cash and cash equivalents	$	-		$	409,882
	Accounts receivable		-			10,581
	Other receivable		-			50,000
	Total current assets		-			470,463

	Goodwill		-			3,299,566
	Total assets	$	-		$	3,770,029

	Liabilities of discontinued segment:

	Accounts payable	$	-		$	110,373
	Accrued expenses		-			125,130
	Advances payable to related party		-			30,590
	Total liabilities	$	-		$	266,093

Current presentation	Amounts presented for the years ended December 31, 2014 and 2013, have been reclassified to conform to the current presentation. The following table provides the amounts reclassified for the years ended December 31, 2014 and 2013:

		For the Year Ended
		December 31,
		2014			2013
	Amounts reclassified:
	Consulting revenue	$	1,612,746		$	3,864,586
	Consulting operating expenses		(1,352,189	)		(1,308,488	)
	Selling and marketing		(27,673	)		(70,069	)
	Impairment expense		(3,299,566	)		(4,258,967	)
	Other income (expense)		(1,725	)		(321,130	)
	Income tax provision		(50,745	)		(344,446	)
	Total amount reclassified as discontinued operations	$	(3,119,152	)	$	(2,438,514	)

6_VARIABLE_INTEREST_ENTITY_Tab

6. VARIABLE INTEREST ENTITY (Tables)	12 Months Ended
6. VARIABLE INTEREST ENTITY (Tables)	Dec. 31, 2014
Variable Interest Entity Tables
Aggregate carrying value of assets and liability	The aggregate carrying value of CBMG Shanghai’s assets and liabilities (after elimination of intercompany transactions and balances) in the Company’s consolidated balance sheets as of December 31, 2014 and 2013 are as follows:

		December 31,		December 31,
		2014		2013
	Assets
	Cash	$	3,496,678	$	9,100
	Accounts receivable		141,029		-
	Other receivable		127,280		50,383
	Inventory		215,152		26,526
	Prepaid expenses		193,613		33,015
	Other current assets		109,777		84,661
	Total current assets		4,283,529		203,685

	Property, plant and equipment, net		1,055,648		772,872
	Intangibles		42,779		54,793
	Long-term prepaid expenses and other assets		126,503		-
	Total assets	$	5,508,459	$	1,031,350

	Liabilities
	Liabilities:
	Accounts payable	$	10,572	$	24,868
	Other payable		714,309		268,301
	Payroll accrual		273,599		74,384
	Tax payable		-		20,150
	Total current liabilities	$	998,480	$	387,703

	Other non-current liabilities		436,346		-
	Total liabilities	$	1,434,826	$	387,703

8_INVENTORY_Tables

8. INVENTORY (Tables)	12 Months Ended
8. INVENTORY (Tables)	Dec. 31, 2014
Inventory Tables
Inventory	At December 31, 2014 and 2013, inventory consisted of the following:

		31-Dec-14		31-Dec-13
	Raw materials	$	128,665	$	27,979
	Work in progress		89,164		-
	Finished goods		154,420		91,140
		$	372,249	$	119,119

9_PROPERTY_PLANT_AND_EQUIPMENT1

9. PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
9. PROPERTY, PLANT AND EQUIPMENT (Tables)	Dec. 31, 2014
Property Plant And Equipment Tables
Property, plant and equipment, carried at cost	As of December 31, 2014 and 2013, property, plant and equipment, carried at cost, consisted of the following:

		31-Dec-14			31-Dec-13

	Office equipment	$	16,842		$	17,100
	Manufacturing equipment		1,518,718			775,449
	Computer equipment		73,888			38,147
	Leasehold improvements		1,414,475			1,049,889
	Construction work in process		-			18,645
			3,023,923			1,899,230
	Less: accumulated depreciation		(1,743,513	)		(884,425	)
		$	1,280,410		$	1,014,805

10_INVESTMENTS_Tables

10. INVESTMENTS (Tables)	12 Months Ended
10. INVESTMENTS (Tables)	Dec. 31, 2014
Schedule of Investments [Abstract]
Assets measured at fair value on a recurring basis

	31-Dec-14	Cost		Gross Unrealized Gains		Gross Unrealized Losses more than 12 months		Gross Unrealized Losses less than 12 months			Market or Fair Value
	Equity position in Alpha Lujo, Inc.	$	251,388	$	42,846	$	-	$	-		$	294,234
	Equity position in Arem Pacific Corporation		5,030,000		1,370,000		-		-			6,400,000
	Equity position in Wonder International Education & Investment Group Corporation		191,799		-		-		-			191,799
	Total	$	5,473,187	$	1,412,846	$	-	$	-		$	6,886,033


	31-Dec-13	Cost		Gross Unrealized Gains		Gross Unrealized Losses more than 12 months		Gross Unrealized Losses less than 12 months			Market or Fair Value
	Equity position in Alpha Lujo, Inc.	$	171,388	$	-	$	-	$	(64,270	)	$	107,118
	Equity position in Arem Pacific Corporation		3,500,000		-		-		-			3,500,000
	Equity position in Wonder International Education & Investment Group Corporation		1,627,239		-		-		(128,466	)		1,498,773
	Total	$	5,298,627	$	-	$	-	$	(192,736	)	$	5,105,891

11_FAIR_VALUE_ACCOUNTING_Table

11. FAIR VALUE ACCOUNTING (Tables)	12 Months Ended
11. FAIR VALUE ACCOUNTING (Tables)	Dec. 31, 2014
Fair Value Accounting Tables
Assets measured at fair value on a recurring basis	Assets measured at fair value on a recurring basis as of December 31, 2014 and 2013 are summarized as follows:

		As of December 31, 2014
		Fair Value Measurements at Reporting Date Using:
				Quoted Prices in		Significant Other		Significant
				Active Markets for		Observable		Unobservable
				Identical Assets		Inputs		Inputs
		Total		(Level 1)		(Level 2)		(Level 3)
	Assets:
	Equity position in Alpha Lujo, Inc.	$	294,234	$	-	$	294,234	$	-
	Equity position in Arem Pacific Corporation		6,400,000		-		6,400,000		-
	Equity position in Wonder International Education & Investment Group Corporation		191,799		-		191,799		-
		$	6,886,033	$	-	$	6,886,033	$	-

		As of December 31, 2013
		Fair Vaue Measurements at Reporting Date Using:
				Quoted Prices in		Significant Other		Significant
				Active Markets for		Observable		Unobservable
				Identical Assets		Inputs		Inputs
		Total		(Level 1)		(Level 2)		(Level 3)
	Assets:
	Equity position in Alpha Lujo, Inc.	$	107,118	$	-	$	107,118	$	-
	Equity position in Arem Pacific Corporation		3,500,000		-		3,500,000		-
	Equity position in Wonder International Education & Investment Group Corporation		1,498,773		-		1,498,773		-
		$	5,105,891	$	-	$	5,105,891	$	-

12_INTANGIBLE_ASSETS_Tables

12. INTANGIBLE ASSETS (Tables)	12 Months Ended
12. INTANGIBLE ASSETS (Tables)	Dec. 31, 2014
Intangible Assets Tables
Intangible assets at cost	As of December 31, 2014 and 2013, intangible assets, consisted of the following:

	Patents
		31-Dec-14			31-Dec-13
	Cost basis	$	11,404,730		$	1,020,577
	Less: accumulated amortization		(289,758	)		(475,381	)
		$	11,114,972		$	545,196

	Software
		31-Dec-14			31-Dec-13
	Cost basis	$	65,848		$	57,031
	Less: accumulated amortization		(24,144	)		(12,479	)
		$	41,704		$	44,552

	Trademark
		31-Dec-14			31-Dec-13
	Cost basis	$	-		$	11,708
	Less: accumulated amortization		-			-
		$	-		$	11,708

	Total intangibles, net	$	11,156,676		$	601,456
Estimated amortization expenses	Estimated amortization expense for each of the ensuing years are as follows for the years ending December 31:

	Years ending December 31,	Amount
	2015	$	1,156,133
	2016		1,156,133
	2017		1,156,133
	2018		1,150,437
	2019 and thereafter		6,537,840
		$	11,156,676

13_LEASES_Tables

13. LEASES (Tables)	12 Months Ended
13. LEASES (Tables)	Dec. 31, 2014
Leases Tables
Future minimum lease payments due	As of December 31, 2014, the Company has the following future minimum lease payments due under the foregoing lease agreements:

	Years ending December 31,	Amount
	2015	$	711,153
	2016		515,654
		$	1,226,807

17_STOCK_BASED_COMPENSATION_Ta

17. STOCK BASED COMPENSATION (Tables)	12 Months Ended
17. STOCK BASED COMPENSATION (Tables)	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock option activity	The following table summarizes stock option activity as of December 31, 2014 and 2013:

		Number of Options			Weighted- Average		Weighted- Average Remaining		Aggregate Intrinsic Value
		Number of Options			Exercise Price		Contractual Term (in years)		Aggregate Intrinsic Value

	Outstanding at December 31, 2013		705,073		$	4.19		9.2	$	735,132
	Grants		795,500			10.53
	Forfeitures		(71,750	)		5.06
	Exercises		(3,650	)		5.31
	Outstanding at December 31, 2014		1,425,173		$	7.37		8.9	$	11,065,770

	Vested and exercisable at December 31, 2014		376,212		$	4.18		8.5	$	3,730,238

Outstanding stock options		Exercise			Number of Options
		Price			Outstanding		Exercisable

		$3.00 - $4.95				350,883		153,662
		$5.00 - $9.19				810,990		222,550
		$14.50+				263,300		-
						1,425,173		376,212

18_NET_INCOME_LOSS_PER_SHARE_T

18. NET INCOME (LOSS) PER SHARE (Tables)	12 Months Ended
18. NET INCOME (LOSS) PER SHARE (Tables)	Dec. 31, 2014
Net Income Loss Per Share Tables
Schedule of basic and diluted earning per share	Basic and diluted net loss per common share is computed on the basis of our weighted average number of common shares outstanding, as determined by using the calculations outlined below:

		For the Year Ended
		December 31,
		2014			2013

	Loss from continuing operations	$	(12,355,459	)	$	(11,358,519	)

	Loss on discontinued operations	$	(3,119,152	)	$	(2,438,514	)

	Net loss	$	(15,474,611	)	$	(13,797,033	)

	Weighted average shares of common stock		8,627,094			5,792,888
	Dilutive effect of stock options		-			-
	Restricted stock vested not issued		-			-
	Common stock and common stock equivalents		8,627,094			5,792,888

	Loss from continuing operations per basic share	$	(1.43	)	$	(1.96	)
	Loss from continuing operations per diluted share	$	(1.43	)	$	(1.96	)

	Loss on discontinued operations per basic share	$	(0.36	)	$	(0.42	)
	Loss on discontinued operations per diluted share	$	(0.36	)	$	(0.42	)

	Net loss per basic share	$	(1.79	)	$	(2.38	)
	Net loss per diluted share	$	(1.79	)	$	(2.38	)

19_INCOME_TAXES_Tables

19. INCOME TAXES (Tables)	12 Months Ended
19. INCOME TAXES (Tables)	Dec. 31, 2014
Income Taxes Tables
Schedule of components of the current tax expense	The following represent components of the current tax expense for the year ended December 31, 2014 and 2013.

		December 31,			December 31,
		2014			2013
	Current tax expense:
	US federal	$	41,798		$	339,856
	US state		8,947			4,590
		$	50,745		$	344,446
Schedule of components of net deferred tax assets	The following represent components of net deferred tax assets at December 31, 2014 and 2013:

		December 31,			December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carry forwards (offshore)	$	4,343,930		$	2,811,207
	Net operating loss carry forwards (US)		1,823,432			-
	Accrued compensation (US)		581,129			294,127
	Stock options (US)		1,217,927			1,909,635
	Investments (US)		599,332			-

	Deferred tax liabilities		-			-

	Subtotal		8,565,750			5,014,969
	Less: valuation allowance		(8,565,750	)		(5,014,969	)
	Net deferred tax asset	$	-		$	-
Schedule of reconciliation of Income tax expense (benefit)	The following table summarizes a reconciliation of Income tax expense (benefit) for the year ended December 31, 2014 compared with the amounts at the U.S. federal statutory rate:

	Effective Tax Rate Reconciliation
	Federal tax		(35.00	)%
	State tax		0.04	%
	Goodwill impairment		7.49	%
	Foreign tax rate difference		13.91	%
	Other permanent difference		0.29	%
	Change in valuation allowance		13.59	%

	Provisional rate		0.32	%

3_SUMMARY_OF_SIGNIFICANT_ACCOU2

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies Details Narrative
Depreciation expense	$586,679	$495,029
Comprehensive loss	13,848,312	13,916,583
Impairment expense	$3,299,566	$4,258,967

4_BUSINESS_COMBINATION_Details

4. BUSINESS COMBINATION (Details) (USD $)	Dec. 31, 2014
Business Combination Details
Cash	$145,611
Accounts receivable	151,093
Other receivable	31,798
Inventory	174,820
Prepaid expenses	14,331
Property, plant and equipment, net	561,113
Intangible assets	9,942,000
Goodwill	7,678,786
Long-term prepaid expenses	83,054
Total assets acquired	18,782,606
Accounts payable	-47,509
Accrued expenses	-42,013
Other current liabilities	-523,077
Other non current liabilities	-422,592
Total liabilities assumed	-1,035,191
Purchase price	$17,747,415

4_BUSINESS_COMBINATION_Details1

4. BUSINESS COMBINATION (Details 1) (USD $)	12 Months Ended
4. BUSINESS COMBINATION (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Net Income (loss)	($15,474,611)	($13,797,033)
Weighted average common shares outstanding:
Basic	8,627,094	5,792,888
Diluted	8,627,094	5,792,888
Earnings (loss) per share
Basic	($1.79)	($2.38)
Diluted	($1.79)	($2.38)
CBMG As stated
Net sales and revenue	564,377	204,914
Net Income (loss)	-15,474,611	-13,797,033
Weighted average common shares outstanding:
Basic	8,627,094	5,792,888
Diluted	8,627,094	5,792,888
Earnings (loss) per share
Basic	($1.79)	($2.38)
Diluted	($1.79)	($2.38)
Agreen Pro forma Adjustment
Net sales and revenue	1,198,414	1,075,692
Net Income (loss)	-48,109	-338,804
Weighted average common shares outstanding:
Basic	555,335	753,522
Diluted	555,335	753,522
Earnings (loss) per share
Basic	($0.09)	($0.45)
Diluted	($0.09)	($0.45)
Pro-forma Consolidated
Net sales and revenue	1,762,791	1,280,606
Net Income (loss)	($15,522,720)	($14,135,837)
Weighted average common shares outstanding:
Basic	9,182,429	6,546,410
Diluted	9,182,429	6,546,410
Earnings (loss) per share
Basic	($1.69)	($2.16)
Diluted	($1.69)	($2.16)

5_DISCONTINUED_OPERATIONS_Deta

5. DISCONTINUED OPERATIONS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Assets of discontinued segment:
Cash and cash equivalents		$409,882
Accounts receivable		10,581
Other receivable		50,000
Total current assets		470,463
Goodwill		3,299,566
Total assets		3,770,029
Liabilities of discontinued segment:
Accounts payable		110,373
Accrued expenses		125,130
Advances payable to related party		30,590
Total liabilities		$266,093

5_DISCONTINUED_OPERATIONS_Deta1

5. DISCONTINUED OPERATIONS (Details 1) (USD $)	12 Months Ended
5. DISCONTINUED OPERATIONS (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Amounts reclassified:
Consulting revenue	$1,612,746	$3,864,586
Consulting operating expenses	-1,352,189	-1,308,488
Selling and marketing	-27,673	-70,069
Impairment expense	-3,299,566	-4,258,967
Other income (expense)	-1,725	-321,130
Income tax provision	-50,745	-344,446
Total amount reclassified as discontinued operations	($3,119,152)	($2,438,514)

6_VARIABLE_INTEREST_ENTITY_Det

6. VARIABLE INTEREST ENTITY (Details) (USD $)	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Assets
Cash	$14,770,584		$7,175,215		$4,144,896
Other receivable	135,957		78,521
Inventory	372,249		119,119
Other current assets	110,347		134,661
Total current assets	16,095,465		7,575,008
Property, plant and equipment, net	1,280,410		1,014,805
Intangibles	11,156,676		601,456
Total assets	43,685,102	[1]	17,596,726	[1]
Liabilities:
Accounts payable	426,917		213,891
Other payable	2,074,384		503,717
Tax payable	814,288		1,164,747
Total current liabilities	4,076,322		2,201,653
Other non-current liabilities	452,689
Total liabilities	4,529,011	[1]	2,201,653	[1]
CBMG Shanghai
Assets
Cash	3,496,678		9,100
Accounts receivable	141,029
Other receivable	127,280		50,383
Inventory	215,152		26,526
Prepaid expenses	193,613		33,015
Other current assets	109,777		84,661
Total current assets	4,283,529		203,685
Property, plant and equipment, net	1,055,648		772,872
Intangibles	42,779		54,793
Long-term prepaid expenses and other assets	126,503
Total assets	5,508,459		1,031,350
Liabilities:
Accounts payable	10,572		24,868
Other payable	714,309		268,301
Payroll accrual	273,599		74,384
Tax payable			20,150
Total current liabilities	998,480		387,703
Other non-current liabilities	436,346
Total liabilities	$1,434,826		$387,703

[1]	The Company's consolidated assets as of December 31, 2014 and 2013 included $5,508,459 and $1,031,350, respectively, of assets of variable interest entities, or VIEs, that can only be used to settle obligations of the VIEs. Each of the following amounts represent the balances as of December 31, 2014 and 2013, respectively. These assets include cash and cash equivalents of $3,496,678 and $9,100; accounts receivable of $141,029 and $0; other receivables of $127,280 and $50,383; inventory of $215,152 and $26,526; prepaid expenses of $193,613 and $33,015; other current assets of $109,777 and $84,661; property, plant and equipment, net, of $1,055,648 and $772,872; and intangibles of $42,779 and $54,793; long-term prepaid expenses and other assets of $126,503 and $0. The Company's consolidated liabilities as of December 31, 2014 and 2013 included $1,434,826 and $387,703, respectively, of liabilities of the VIEs whose creditors have no recourse to the Company. These liabilities include accounts payable of $10,572 and $24,868; other payables of $714,309 and $268,301; payroll accrual of $273,599 and $74,384; and tax payable of $0 and $20,150 and other non-current liabilities of $436,346 and $0. See further description in Note 6, Variable Interest Entity.

7_OTHER_CURRENT_ASSETS_Details

7. OTHER CURRENT ASSETS (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Other Current Assets Details Narrative
Other Current Liabilities	$135,957	$78,521

8_INVENTORY_Details

8. INVENTORY (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory Details
Raw materials	$128,665	$27,979
Work in progress	89,164
Finished goods	154,420	91,140
Inventory Total	$372,249	$119,119

9_PROPERTY_PLANT_AND_EQUIPMENT2

9. PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Gross Property plant and equipment	$3,023,923	$1,899,230
Less: accumulated depreciation	-1,743,513	-884,425
Net Property plant and equipment	1,280,410	1,014,805
Office equipment
Gross Property plant and equipment	16,842	17,100
Manufacturing equipment
Gross Property plant and equipment	1,518,718	775,449
Computer equipment
Gross Property plant and equipment	73,888	38,147
Leasehold improvements
Gross Property plant and equipment	1,414,475	1,049,889
Construction work in process
Gross Property plant and equipment		$18,645

9_PROPERTY_PLANT_AND_EQUIPMENT3

9. PROPERTY, PLANT AND EQUIPMENT (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment Details Narrative
Depreciation expense	$586,679	$495,029

10_INVESTMENTS_Details

10. INVESTMENTS (Details) (USD $)	12 Months Ended
10. INVESTMENTS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Cost	$5,473,187	$5,298,627
Gross Unrealized Gains	1,412,846
Gross Unrealized Losses more than 12 months
Gross Unrealized Losses less than 12 months		-192,736
Market or Fair Value	6,886,033	5,105,891
Equity position in Alpha Lujo, Inc.
Cost	251,388	171,388
Gross Unrealized Gains	42,846
Gross Unrealized Losses more than 12 months
Gross Unrealized Losses less than 12 months		-64,270
Market or Fair Value	294,234	107,118
Equity position in Arem Pacific Corporation
Cost	5,030,000	3,500,000
Gross Unrealized Gains	1,370,000
Gross Unrealized Losses more than 12 months
Gross Unrealized Losses less than 12 months
Market or Fair Value	6,400,000	3,500,000
Equity position in Wonder International Education & Investment
Cost	191,799	1,627,239
Gross Unrealized Gains
Gross Unrealized Losses more than 12 months
Gross Unrealized Losses less than 12 months		-128,466
Market or Fair Value	$191,799	$1,498,773

11_FAIR_VALUE_ACCOUNTING_Detai

11. FAIR VALUE ACCOUNTING (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Equity position	$6,886,033	$5,105,891
Equity position in Alpha Lujo, Inc.
Equity position	294,234	107,118
Equity position in Wonder International Education & Investment Group Corporation
Equity position	191,799	1,498,773
Equity position in Arem Pacific Corporation Member
Equity position	6,400,000	3,500,000
Level 1
Equity position
Level 1 \| Equity position in Alpha Lujo, Inc.
Equity position
Level 1 \| Equity position in Wonder International Education & Investment Group Corporation
Equity position
Level 1 \| Equity position in Arem Pacific Corporation Member
Equity position
Level 2
Equity position	6,886,033	5,105,891
Level 2 \| Equity position in Alpha Lujo, Inc.
Equity position	294,234	107,118
Level 2 \| Equity position in Wonder International Education & Investment Group Corporation
Equity position	191,799	1,498,773
Level 2 \| Equity position in Arem Pacific Corporation Member
Equity position	6,400,000	3,500,000
Level 3
Equity position
Level 3 \| Equity position in Alpha Lujo, Inc.
Equity position
Level 3 \| Equity position in Wonder International Education & Investment Group Corporation
Equity position
Level 3 \| Equity position in Arem Pacific Corporation Member
Equity position

11_FAIR_VALUE_ACCOUNTING_Detai1

11. FAIR VALUE ACCOUNTING (Details Narrative)	Dec. 31, 2014	Dec. 31, 2013
Equity position in Arem Pacific Corporation Member
Shares Issued as compensation for services	3,000,000	5,000,000
Shares held by the company	8,000,000	5,000,000
Equity position in Wonder International Education & Investment Group Corporation
Shares held by the company	2,131,105	2,141,105
Equity position in Alpha Lujo, Inc.
Shares Issued as compensation for services	800,000
Shares held by the company	2,942,350	2,142,350

12_INTANGIBLE_ASSETS_Details

12. INTANGIBLE ASSETS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Total	$11,156,676	$601,456
Patents [Member]
Cost basis	11,404,730	1,020,577
Less: accumulated amortization	-289,758	-475,381
Total	11,114,972	545,196
Software [Member]
Cost basis	65,848	57,031
Less: accumulated amortization	-24,144	-12,479
Total	41,704	44,552
Trademarks [Member]
Cost basis		11,708
Less: accumulated amortization
Total		$11,708

12_INTANGIBLE_ASSETS_Details_1

12. INTANGIBLE ASSETS (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Intangible Assets Details 1
2015	$1,156,133
2016	1,156,133
2017	1,156,133
2018	1,150,437
2019 and thereafter	6,537,840
Total	$11,156,676	$601,456

12_INTANGIBLE_ASSETS_Details_N

12. INTANGIBLE ASSETS (Details Narrative) (USD $)	12 Months Ended
12. INTANGIBLE ASSETS (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Amortization expense	$603,826	$346,206
Software [Member]
Intangible assets estimated useful life	5 years
Patents [Member] \| Minimum [Member]
Intangible assets estimated useful life	5 years
Patents [Member] \| Maximum [Member]
Intangible assets estimated useful life	10 years

13_LEASES_Details

13. LEASES (Details) (USD $)	Dec. 31, 2014
Leases Details
2015	$711,153
2016	515,654
Total	$1,226,807

13_LEASES_Details_Narrative

13. LEASES (Details Narrative) (USD $)	12 Months Ended
13. LEASES (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Leases Details Narrative
Rent Expense	$576,000	$454,000

14_RELATED_PARTY_TRANSACTIONS_

14. RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	12 Months Ended
14. RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Related Party Transactions Details Narrative
Due to related parties	$36,254	$67,999
Accrued Compensation Liability to officers	6,037	37,784
Accrued Compensation Liability to a subsidiary	30,217	30,215
Revenues - Products	179,000	204,900
Amount paid for settlement of outstanding accrued compensation liabilities	$1,493,439

15_EQUITY_Details_Narrative

15. EQUITY (Details Narrative) (USD $)	12 Months Ended
15. EQUITY (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Notes to Financial Statements
Stock based compensation, shares	13,413	65,000
Stock based compensation	207,201	386,250
Exercise of stock options, shares	3,650
Exercise of stock options	$19,387
Unvested restricted and option awards	1,742,703	792,645
Unvested restricted and option awards vest period	3 years	3 years
Reverse merger, shares outstanding	1,570,299
Reverse merger, shares issued	3,638,941
Common stock issued for services, shares		231,384
Common stock issued for services, amount	578,981	1,157,099
Common stock issued to employee in connection with merger, shares		71,814
Common stock issued to employee in connection with merger		350,402
Contingent stock issuance, shares		342,360
Contingent stock issuance		1,694,682
Common stock issued for services Expenses		$1,157,099

17_STOCK_BASED_COMPENSATION_De

17. STOCK BASED COMPENSATION (Details) (USD $)	12 Months Ended
17. STOCK BASED COMPENSATION (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Exercised	3,650
Ending Balance	1,425,173
Equity Option [Member]
Beginning Balance	705,073
Granted	795,500
Forfeited or expired	-71,750
Exercised	-3,650
Ending Balance	1,425,173	705,073
Vested and exercisable	376,212
Weighted Average Exercise Price, Outstanding Beggining Balance	$4.19
Weighted Average Exercise Price, Granted	$10.53
Weighted Average Exercise Price, Forfeited or expired	$5.06
Weighted Average Exercise Price, Exercised	$5.31
Weighted Average Exercise Price, Outstanding Ending Balance	$7.37	$4.19
Weighted Average Exercise Price, Vested and exercisable	$4.18
Weighted-Average Remaining Contractual Term, Outstanding	8 years 10 months 24 days	9 years 2 months 12 days
Weighted-Average Remaining Contractual Term, Vested and exercisable	8 years 6 months
Aggregate Intrinsic Value, Outstanding	$11,065,770	$735,132
Aggregate Intrinsic Value, Vested and exercisable	$3,730,238

17_STOCK_BASED_COMPENSATION_De1

17. STOCK BASED COMPENSATION (Details 1) (USD $)	Dec. 31, 2014
Number of Shares Outstanding	1,425,173
Outstanding stock options,Exerciseable	376,212
Minimum [Member]
Outstanding stock options Exercise Price	5
Maximum [Member]
Outstanding stock options Exercise Price	28.49
Stock Option One [Member]
Number of Shares Outstanding	350,883
Outstanding stock options,Exerciseable	153,662
Stock Option One [Member] \| Minimum [Member]
Outstanding stock options Exercise Price	3
Stock Option One [Member] \| Maximum [Member]
Outstanding stock options Exercise Price	4.95
Stock Option Two [Member]
Number of Shares Outstanding	810,990
Outstanding stock options,Exerciseable	222,550
Stock Option Two [Member] \| Minimum [Member]
Outstanding stock options Exercise Price	5
Stock Option Two [Member] \| Maximum [Member]
Outstanding stock options Exercise Price	9.19
Stock Option Three [Member]
Outstanding stock options Exercise Price	14.5
Number of Shares Outstanding	263,300
Outstanding stock options,Exerciseable

17_STOCK_BASED_COMPENSATION_De2

17. STOCK BASED COMPENSATION (Details Narrative) (USD $)	12 Months Ended
17. STOCK BASED COMPENSATION (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Shares issued under 2011 and 2013 Incentive Plan	795,500
Grant date fair value of the options	$6,884,822
Expected lives	6 years
Minimum Risk-free interest rate	1.77%
Maximum Risk-free interest rate	2.08%
Minimum [Member]
Stock exercise price	$5
Expected volatility	112.00%
Maximum [Member]
Stock exercise price	$28.49
Expected volatility	130.00%
2011 Incentive Stock Option Plan
Stock-based compensation	1,949,904	1,529,297
Unrecognized compensation cost related to non-vested stock option awards	7,642,709
Non-vested stock option awards	1,048,961
Unrecognized compensation cost related to non-vested restricted stock awards	$97,748
Non-vested restricted stock	7,115

18_NET_INCOME_LOSS_PER_SHARE_D

18. NET INCOME (LOSS) PER SHARE (Details) (USD $)	12 Months Ended
18. NET INCOME (LOSS) PER SHARE (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Net Income Loss Per Share Details
Loss from continuing operations	($12,355,459)	($11,358,519)
Loss on discontinued operations	-3,119,152	-2,438,514
Net loss	($15,474,611)	($13,797,033)
Weighted average shares of common stock	8,627,094	5,792,888
Dilutive effect of stock options
Restricted stock vested not issued
Common stock and common stock equivalents	8,627,094	5,792,888
Loss from continuing operations per basic share	($1.43)	($1.96)
Loss from continuing operations per diluted share	($1.43)	($1.96)
Loss on discontinued operations per basic share	($0.36)	($0.42)
Loss on discontinued operations per diluted share	($0.36)	($0.42)
Net loss per basic share	($1.79)	($2.38)
Net loss per diluted share	($1.79)	($2.38)

19_INCOME_TAXES_Details

19. INCOME TAXES (Details) (USD $)	12 Months Ended
19. INCOME TAXES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current tax expense:
US federal	$41,798	$339,856
US state	8,947	4,590
Current tax expense	$50,745	$344,446

19_INCOME_TAXES_Details_1

19. INCOME TAXES (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforwards (offshore)	$4,343,930	$2,811,207
Net operating loss carryforwards (US)	1,823,432
Accrued compensation (US)	581,129	294,127
Stock options (US)	1,217,927	1,909,635
Investments (US)	599,332
Deferred tax liabilities
Subtotal	8,565,750	5,014,969
Less: valuation allowance	-8,565,750	-5,014,969
Net deferred tax assets

19_INCOME_TAXES_Details_2

19. INCOME TAXES (Details 2)	12 Months Ended
19. INCOME TAXES (Details 2)	Dec. 31, 2014
Effective Tax Rate Reconciliation
Federal tax	-35.00%
State tax	0.04%
Goodwill impairment	7.49%
Foreign tax rate difference	13.91%
Other permanent difference	0.29%
Change in valuation allowance	13.59%
Provisional rate	0.32%

19_INCOME_TAXES_Details_Narrat

19. INCOME TAXES (Details Narrative) (USD $)	12 Months Ended
19. INCOME TAXES (Details Narrative) (USD $)	Dec. 31, 2014
U.S Federal [Member]
Net operating loss carryforwards	$4,300,000
Losses expiration period	31-Dec-34
Effective tax rate	35.00%
U.S. State [Member]
Net operating loss carryforwards	4,300,000
Losses expiration period	31-Dec-34
Chinese [Member]
Net operating loss carryforwards	$24,700,000
Losses expiration period	31-Dec-19
Effective tax rate	25.00%